[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4713
6. Prezeau N, Silvy M, Gabert J, Picard C: Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol. Leuk Res; 2006 May;30(5):569-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol.
  • PAXgene Blood was already validated to monitor minimal residual disease (MRD) in onco-hematologic pathologies.
  • Altogether, our data suggest the possible use of such a technology for MRD follow-up in myeloproliferative diseases and acute leukemias.
  • [MeSH-major] Hematologic Neoplasms / diagnosis. Neoplasm, Residual / diagnosis. RNA / analysis. RNA Stability. Reagent Kits, Diagnostic. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Cell Line, Tumor. Europe. Humans. Indicators and Reagents / chemistry. K562 Cells. Oncogene Proteins, Fusion / genetics. Reproducibility of Results. Sensitivity and Specificity. Transcription, Genetic

  • Biospecimen Research Database. Biospecimen Research Database .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209886.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indicators and Reagents; 0 / Oncogene Proteins, Fusion; 0 / Reagent Kits, Diagnostic; 63231-63-0 / RNA
  •  go-up   go-down


7. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS, Children's Oncology Group: Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol; 2008 Oct;143(2):261-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group.
  • Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy.
  • We report the results of a pilot study to estimate the feasibility, toxicity and efficacy of a 12-month aggressive multi-agent chemotherapy regimen in children and adolescents with advanced LL.
  • There were a total of 19 events, 13 relapses, two secondary acute myeloid leukaemia and four toxic deaths (5%).
  • Multivariate analysis failed to demonstrate age, gender, lactate dehydrogenase level, presence of marrow and/or central nervous system disease to have independent prognostic value.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):840-6 [18342502.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):537-41 [6689428.001]
  • [Cites] Br J Cancer. 1984 Oct;50(4):457-62 [6333247.001]
  • [Cites] Blood. 1985 Nov;66(5):1110-4 [3840395.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):744-52 [3517244.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Br J Haematol. 1992 Oct;82(2):310-6 [1419812.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):130-40 [16358311.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • (PMID = 18759768.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / U10 CA098543-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS107033; NLM/ PMC3057023
  •  go-up   go-down


8. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, Chaffanet M, Maraninchi D, Viens P, Birnbaum D: How different are luminal A and basal breast cancers? Int J Cancer; 2009 Mar 15;124(6):1338-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genes associated with proliferation, cell cycle, cell motility, angiogenesis, and NFkB signalling were overexpressed in basal tumours.
  • The number of differentially expressed genes was as high as the set of genes discriminating 2 cancers of different anatomical origin (breast and colon) or discriminating acute myeloid and lymphoid leukaemia.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058218.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen
  •  go-up   go-down


9. Tansley S, Gibbons S: Capecitabine-induced acute myeloid leukaemia. N Z Med J; 2009 May 8;122(1294):118-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine-induced acute myeloid leukaemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Leukemia, Myeloid, Acute / chemically induced

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465957.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA, EUROCARE Working Group: Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer; 2009 Apr;45(6):992-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival improved significantly over time for acute lymphoid leukaemia and primitive neuroectodermal tumours in children and for non-Hodgkin lymphoma in adolescents/young adults.
  • Complete cancer registration should be a priority for these countries as an essential part of a policy for effective cancer control in Europe.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231160.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Oberaigner W; Hackl M; Van Eycken E; Verstreken M; Holub J; Jurickova L; Storm HH; Engholm G; Hakulinen T; Belot A; Hédelin G; Velten M; Tron I; Le Gall E; Launoy G; Guizard AV; Faivre J; Bouvier AM; Carli PM; Maynadié M; Danzon A; Buemi A; Tretarre B; Lacour B; Desandes E; Colonna M; Molinié F; Bara S; Schvartz S; Ganry O; Grosclaude P; Brenner H; Kaatsch P; Ziegler H; Tryggvadottir L; Comber H; Berrino F; Allemani C; Baili P; Ciampichini R; Ciccolallo L; Gatta G; Micheli A; Sant M; Sowe S; Zigon G; Tagliabue G; Contiero P; Bellù F; Giacomin A; Ferretti S; Dal Maso DS; De Dottori M; De Paoli A; Zanier L; Vercelli M; Orengo MA; Casella C; Quaglia A; Pannelli F; Federico M; Rashid I; Cirilli C; Fusco M; Traina A; De Lisi V; Bozzani F; Magnani C; Pastore G; Tumino R; La Rosa MG; Spata E; Sigona A; Mangone L; Falcini F; Foca F; Giorgetti S; Senatore G; Iannelli A; Budroni M; Zanetti R; Patriarca S; Rosso S; Piffer S; Franchini S; Paci E; Crocetti E; La Rosa F; Stracci F; Cassetti T; Zambon P; Guzzinati S; Caldora M; Capocaccia R; Carrani E; De Angelis R; Francisci S; Grande E; Inghelmann R; Lenz H; Martina L; Roazzi P; Santaquilani M; Simonetti A; Tavilla A; Verdecchia A; Dalmas M; Langmark F; Bray F; Johannesen TB; Rachtan J; Góźdź S; Siudowska U; Mezyk R; Bielska-Lasota M; Zwierko M; Pinheiro PS; Primic-Zakelj M; Mateos A; Izarzugaza I; Torrella-Ramos A; Zurriaga O; Marcos-Gragera R; Vilardell ML; Izquierdo A; Martinez-Garcia C; Sánchez MJ; Navarro C; Chirlaque MD; Peris-Bonet R; Ardanaz E; Moreno C; Galceran J; Klint A; Talbäck M; Jundt G; Usel M; Frick H; Ess SM; Bordoni A; Luthi JC; Konzelmann I; Probst N; Lutz JM; Pury P; Visser O; Otter R; Schaapveld M; Coebergh JW; Janssen-Heijnen ML; van der Heijden L; Greenberg DC; Coleman MP; Woods L; Moran T; Forman D; Cooper N; Roche M; Verne J; Møller H; Meechan D; Poole J; Lawrence G; Stiller C; Gavin A; Black RJ; Brewster DH; Steward JA
  •  go-up   go-down


11. Choo A, Palladinetti P, Holmes T, Basu S, Shen S, Lock RB, O'Brien TA, Symonds G, Dolnikov A: siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth. Int J Oncol; 2008 Jul;33(1):175-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth.
  • Control of cell growth has led to the definition of IRF1 as a tumour suppressor gene and IRF2 as an oncogene.
  • Clinically, approximately 70% of cases of acute myeloid leukaemia demonstrate dysregulated expression of IRF1 and/or IRF2.
  • In contrast to these results, siIRF2 targeting did not affect normal haematopoietic stem/progenitor cell growth.
  • [MeSH-major] Interferon Regulatory Factor-2 / antagonists & inhibitors. Leukemia / therapy. RNA, Small Interfering / genetics
  • [MeSH-minor] Antigens, CD14 / analysis. Antigens, CD34 / analysis. Cell Cycle. Cell Line, Tumor. Hematopoiesis. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575764.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antigens, CD34; 0 / IRF2 protein, human; 0 / Interferon Regulatory Factor-2; 0 / RNA, Small Interfering
  •  go-up   go-down


12. Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H, Watanabe M, Watanabe K, Kamitsuji Y, Hayashi Y, Tsukimoto I, Kobayashi R, Horibe K, Tawa A, Nakahata T, Adachi S: Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group. Int J Hematol; 2010 Jun;91(5):831-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
  • High BAALC (brain and acute leukemia, cytoplasmic) gene expression may indicate an adverse prognosis for adults who have acute myeloid leukemia (AML) and a normal karyotype, but its prognostic significance for pediatric AML cases is unclear.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. CCAAT-Enhancer-Binding Proteins. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / diagnosis. Mutation. Neoplasm Proteins


13. Valent P: Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev; 2009 Jul;23(4):157-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In stem cell- and myelopoietic neoplasms, eosinophils are derived from the malignant clone, whereas in lymphoid neoplasms and reactive states, eosinophilia is usually triggered by eosinopoietic cytokines.
  • Myeloid neoplasms typically presenting with eosinophilia include chronic myeloid leukemia, chronic eosinophilic leukemia (CEL), other myeloproliferative neoplasms, some acute leukemias, advanced mast cell disorders, and rare forms of myelodysplastic syndromes.
  • In such patients, a thorough hematologic work-up including bone marrow histology and immunohistochemistry, cytogenetics, molecular markers, and a complete staging of potentially affected organ systems has to be initiated.
  • Treatment of hypereosinophilic patients depends on the variant of disease, presence of end organ damage, molecular targets, and the overall situation in each case.
  • [MeSH-major] Eosinophilia / diagnosis. Eosinophilia / drug therapy. Eosinophils / metabolism. Myeloproliferative Disorders / complications

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246139.001).
  • [ISSN] 1532-1681
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 74
  •  go-up   go-down


1
Advertisement
4. Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VP, Deshpande AJ, Heilmeier B, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C: A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med; 2008 Mar 17;205(3):515-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Deregulation of this pathway has been linked to a large variety of cancers, including different subtypes of leukemia.
  • Here, we demonstrate Lef-1 expression in murine HSCs as well as its expression in human leukemia.
  • Mice transplanted with bone marrow retrovirally transduced to express Lef-1 or a constitutive active Lef-1 mutant showed a severe disturbance of normal hematopoietic differentiation and finally developed B lymphoblastic and acute myeloid leukemia (AML).
  • Furthermore, single cell experiments and limiting dilution transplantation assays demonstrated that Lef-1-induced AML was propagated by a leukemic stem cell with lymphoid characteristics displaying Ig DH-JH rearrangements and a B220(+) myeloid marker(-) immunophenotype.
  • These data indicate a thus far unknown role of Lef-1 in the biology of acute leukemia, pointing to the necessity of balanced Lef-1 expression for an ordered hematopoietic development.
  • [MeSH-major] Leukemia / etiology. Lymphoid Enhancer-Binding Factor 1 / metabolism. Wnt Proteins / metabolism
  • [MeSH-minor] Animals. Gene Expression. Hematopoiesis / genetics. Hematopoiesis / physiology. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / metabolism. Humans. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Mice. Neoplastic Stem Cells / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2000 Jul;13(1):15-24 [10933391.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):363-74 [17097559.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):137-47 [12110174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10008-13 [12105272.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S96-104 [12169536.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):817-22 [14718672.001]
  • [Cites] Genes Dev. 2004 Feb 15;18(4):411-22 [15004008.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):653-61 [9034144.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] Immunity. 1998 Jan;8(1):11-20 [9462507.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):21-30 [15630426.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2159-68 [16025155.001]
  • [Cites] Immunity. 2005 Dec;23(6):599-609 [16356858.001]
  • [Cites] Semin Immunol. 2006 Feb;18(1):12-9 [16431127.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2294-303 [16887990.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1048-56 [16951689.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1191-7 [17063141.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7537-44 [11604490.001]
  • (PMID = 18316418.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LEF1 protein, human; 0 / Lef1 protein, mouse; 0 / Lymphoid Enhancer-Binding Factor 1; 0 / RNA, Messenger; 0 / Wnt Proteins
  • [Other-IDs] NLM/ PMC2275375
  •  go-up   go-down


15. Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanné-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ: Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood; 2007 Sep 1;110(5):1648-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
  • Severe congenital neutropenia (SCN) is an inborn disorder of granulopoiesis.
  • Like most other bone marrow failure syndromes, it is associated with a marked propensity to transform into a myelodysplastic syndrome (MDS) or acute leukemia, with a cumulative rate of transformation to MDS/leukemia that exceeds 20%.
  • In this study, we performed mutational profiling of 14 genes previously implicated in leukemogenesis using 14 MDS/leukemia samples from patients with SCN.
  • The sensitivity and specificity of the sequencing pipeline was validated by determining the frequency of mutations in these 14 genes using 188 de novo AML samples.
  • As expected, mutations of tyrosine kinase genes (FLT3, KIT, and JAK2) were common in de novo AML, with a cumulative frequency of 30%.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):483-92 [9691084.001]
  • [Cites] Haematologica. 2000 Nov;85(11):1207-10 [11064470.001]
  • [Cites] J Exp Med. 1999 Feb 15;189(4):683-92 [9989983.001]
  • [Cites] Acta Paediatr Suppl. 1956 Feb;45(Suppl 105):1-78 [13326376.001]
  • [Cites] Haematologica. 2005 Jan;90(1):45-53 [15642668.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Leukemia. 2005 Mar;19(3):329-34 [15674366.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1419-22 [15870172.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2232-40 [16281072.001]
  • [Cites] Blood. 2006 May 15;107(10):3847-53 [16434492.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Leukemia. 2006 Jun;20(6):971-8 [16598306.001]
  • [Cites] J Toxicol Environ Health A. 2000 Nov;61(5-6):381-6 [11086943.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Blood. 2002 May 1;99(9):3129-35 [11964274.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Aug 1;100(3):998-1007 [12130514.001]
  • [Cites] Blood. 2003 Feb 1;101(3):822-6 [12393424.001]
  • [Cites] Genome Res. 2003 May;13(5):954-64 [12695328.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1474-9 [12702504.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3850; author reply 3850-1 [14597609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14275-80 [14614138.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):305-13 [14695343.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Mar;39(3):217-23 [14732923.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] J Mol Biol. 1970 Mar;48(3):443-53 [5420325.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Jan;51(1):1-12 [1984836.001]
  • [Cites] Blood. 1993 May 15;81(10):2496-502 [8490166.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4480-4 [7514305.001]
  • [Cites] N Engl J Med. 1995 Aug 24;333(8):487-93 [7542747.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4579-86 [8541548.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):527-33 [8652369.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):279-84 [8759887.001]
  • [Cites] Leukemia. 1997 Jan;11(1):120-5 [9001427.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2369-75 [9116280.001]
  • [Cites] Leukemia. 1997 Jul;11(7):1005-8 [9204982.001]
  • [Cites] Genome Res. 1998 Mar;8(3):175-85 [9521921.001]
  • [Cites] Genome Res. 1998 Mar;8(3):186-94 [9521922.001]
  • [Cites] Blood. 1998 Jul 1;92(1):32-9 [9639496.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1235-9 [16533529.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1596-604 [17145595.001]
  • [Cites] Blood. 2007 Jan 1;109(1):93-9 [16985178.001]
  • [Cites] Genome Res. 2007 May;17(5):659-66 [17416743.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2113-9 [15951308.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3747-54 [16109776.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4628-35 [16497969.001]
  • [Cites] Semin Hematol. 2006 Jul;43(3):189-95 [16822461.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]
  • [Cites] Semin Hematol. 2000 Jan;37(1):91-101 [10676914.001]
  • [Cites] Br J Haematol. 2000 Feb;108(2):346-56 [10691865.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2132-7 [10706885.001]
  • [Cites] Blood. 2000 Jul 15;96(2):429-36 [10887102.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2862-9 [11023523.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • (PMID = 17494858.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA101140; United States / NCI NIH HHS / CA / CA101937; United States / NCI NIH HHS / CA / P01 CA101937; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CSF3R protein, human; 0 / Neoplasm Proteins; 0 / Receptors, Colony-Stimulating Factor; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC1975847
  •  go-up   go-down


16. Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA: Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology; 2005;69(5):372-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient developed acute leukemia.
  • Sixty-nine (81%) patients are alive, and 59 (69%) patients are alive and free of distant disease at a median follow-up of 5 years.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319508.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA16359
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


17. Tavil B, Cetin M, Tuncer M: CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome. Leuk Res; 2006 Feb;30(2):222-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders that are characterized by morphology identifying dysplastic changes in one or more cell lineages, peripheral blood cytopenias and a propensity to evolve into secondary acute myeloid leukemia (AML).
  • CD34 is commonly expressed in all types of childhood leukemias, whereas CD117 is a reliable and specific marker to detect leukemia cells committed to myeloid lineage.
  • Co-expression of CD34/CD117 may strongly suggest the diagnosis of AML (Rytting ME.
  • May; Uçkan D, Hiçsönmez G, Yetgin S, Gürgey A, Cetin M, Karaağaoğlu E, et al. CD34/CD117 co-expression in childhood acute leukemia.
  • Leukemia Res 2000;24:201-6.).
  • We describe the case of a 22 month-old-girl with MDS and Down syndrome who was presented with severe anemia and thrombocytosis at diagnosis, transformed into AML-M7.
  • In our patient, CD34 and CD117 markers were positive on the blast cells of the BM 6 months before the chemotherapy decision.
  • As the disease progressed, CD34/117 co-existence was increased and MDS transformed into AML.
  • As a result, an increase in CD34 and CD117 positivity of the BM blast cells may be associated with a higher risk of leukemic transformation.
  • [MeSH-minor] Bone Marrow Examination. Female. Humans. Infant. Leukemia, Myeloid, Acute / etiology. Prognosis


18. Massimo LM, Wiley TJ, Bonassi S, Caprino D: Longitudinal psychosocial outcomes in two cohorts of adult survivors from childhood acute leukemia treated with or without cranial radiation. Minerva Pediatr; 2006 Feb;58(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal psychosocial outcomes in two cohorts of adult survivors from childhood acute leukemia treated with or without cranial radiation.
  • AIM: In 1982, 60 children affected by acute lymphoblastic leukemia, treated between 1974 and 1978 with or without cranial radiation, in complete remission, and 2 years at least after stopping therapy, were submitted to a detailed psychological investigation.
  • Most of them did not even know the name of their disease.
  • [MeSH-major] Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Survivors / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541001.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


19. Liang DC, Shih LY, Fu JF, Li HY, Wang HI, Hung IJ, Yang CP, Jaing TH, Chen SH, Liu HC: K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer; 2006 Feb 15;106(4):950-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements.
  • The objective of this study was to investigate the association of Ras mutations with childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with special reference to the presence or absence of mixed-lineage leukemia gene (MLL) rearrangements.
  • METHODS: Bone marrow samples from 313 children with B-precursor ALL and 130 children with de novo AML were studied at diagnosis.
  • RESULTS: Twenty of 313 patients with B-precursor ALL and 17 of 130 patients with de novo AML had MLL rearrangements.
  • [MeSH-major] Gene Rearrangement. Genes, ras. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Blotting, Southern. Child. Child, Preschool. DNA Mutational Analysis. Female. Humans. Infant. Male. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16404744.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Li Y, Zhang R, Lu XL, Wang PP, Fan H, Lü XY: [Tryptase relation to VEGF in acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct;13(5):793-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tryptase relation to VEGF in acute leukemia].
  • In order to investigate the role of tryptase in angiogenesis of acute leukemia (AL), the expressions of tryptase and vascular endothelial growth factor (VEGF) in leukemic cells from 61 patients with AL were examined by using immunocytochemical method, and the correlation between tryptase and VEGF was analyzed.
  • The results showed that tryptase positive expression was found in 15 out of 51 patients with acute myeloid leukemia (AML) (M(1) 1/3, M(2) 7/15, M(3) 5/20, M(5) 2/8).
  • However, none of 10 patients with acute lymphocytic leukemia (ALL) showed tryptase expression.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277844.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


21. Jun DY, Kim JS, Park HS, Han CR, Fang Z, Woo MH, Rhee IK, Kim YH: Apoptogenic activity of auraptene of Zanthoxylum schinifolium toward human acute leukemia Jurkat T cells is associated with ER stress-mediated caspase-8 activation that stimulates mitochondria-dependent or -independent caspase cascade. Carcinogenesis; 2007 Jun;28(6):1303-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptogenic activity of auraptene of Zanthoxylum schinifolium toward human acute leukemia Jurkat T cells is associated with ER stress-mediated caspase-8 activation that stimulates mitochondria-dependent or -independent caspase cascade.
  • After the treatment of Jurkat T cells with AUR, the endoplasmic reticulum (ER) stress-mediated activation of caspase-12 and -8 and subsequent apoptotic events including c-Jun N-terminal kinase (JNK) activation, cleavage of FLICE inhibitory protein and Bid, mitochondrial cytochrome c release, activation of caspase-9 and -3, degradation of poly (ADP-ribose) polymerase and apoptotic DNA fragmentation were induced in a dose-dependent manner.
  • The individual or simultaneous addition of the m-calpain inhibitor (E64d), JNK inhibitor (SP600125) and mitochondrial permeability transition pore inhibitor (CsA) failed to prevent apoptotic events including caspase-8 activation and Bid cleavage, unless the caspase-8 inhibitor (z-IETD-fmk) was combined, whereas AUR-induced caspase-12 activation was sustained even in the concomitant presence of z-IETD-fmk.
  • [MeSH-major] Apoptosis / drug effects. Caspase 8 / metabolism. Coumarins / pharmacology. Endoplasmic Reticulum / enzymology. Leukemia-Lymphoma, Adult T-Cell / enzymology. Leukemia-Lymphoma, Adult T-Cell / pathology. Mitochondria / enzymology. Zanthoxylum

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301064.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coumarins; 495-02-3 / aurapten; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


22. Tamai H, Inokuchi K: 11q23/MLL acute leukemia : update of clinical aspects. J Clin Exp Hematop; 2010;50(2):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11q23/MLL acute leukemia : update of clinical aspects.
  • Rearrangements of the MLL gene located at 11q23 are common chromosomal abnormalities associated with acute leukemia (AL), especially infant and secondary leukemia after previous treatment with DNA topoisomerase II inhibitors.
  • Recent studies showed that the prognosis of 11q23/MLL AL varies widely according to the partner gene, the leukemia cell lineage, the age of the patient and the treatment administered.
  • Special strategies are needed to treat 11q23/MLL AL, including allogeneic hematopoietic stem cell transplantation, according to the fusion partner.
  • The development of novel methodologies, including new molecular therapeutic targets, is also needed to improve the prognosis of 11q23/MLL AL.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Leukemia / genetics. Myeloid-Lymphoid Leukemia Protein / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21123966.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


23. Rüping MJ, Vehreschild JJ, Cornely OA: Antifungal treatment strategies in high risk patients. Mycoses; 2008 Sep;51 Suppl 2:46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discuss different strategies for the treatment of invasive fungal infections (IFI) in high risk patients with a focus on patients experiencing profound and prolonged neutropenia, comprising those with acute myelogenous leukaemia (AML) or myelodysplastic syndrome (MDS) during remission induction chemotherapy and on patients undergoing allogeneic haematopoietic stem cell transplantation (SCT).
  • In allogeneic HSCT recipients, patients receiving induction chemotherapy for AML or MDS and those under immunosuppressive medication for graft vs. host disease after allogeneic HSCT, we recommend prophylaxis with posaconazole.
  • If the diagnosis of IA can be established, voriconazole should be favoured over the alternative, liposomal amphotericin B (L-AmB).
  • In non-neutropenic patients, we recommend an echinocandin as the first line treatment option.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721331.001).
  • [ISSN] 1439-0507
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


24. Capello D, Deambrogi C, Rossi D, Lischetti T, Piranda D, Cerri M, Spina V, Rasi S, Gaidano G, Lunghi M: Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol; 2008 May;141(4):504-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated epigenetic and genetic inactivation of SOCS3, SOCS1 and PTPN6 in 112 CMPD and 20 acute myeloid leukaemia (AML) post-CMPD.
  • [MeSH-minor] Chronic Disease. DNA Methylation. Disease Progression. Humans. Janus Kinase 2 / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Mutation. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Philadelphia Chromosome. Protein Tyrosine Phosphatase, Non-Receptor Type 6 / genetics. Protein Tyrosine Phosphatase, Non-Receptor Type 6 / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318760.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / SOCS1 protein, human; 0 / SOCS3 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 3.1.3.48 / PTPN6 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6
  •  go-up   go-down


25. Niedzielska E, Wójcik D, Barg E, Pietras W, Sega-Pondel D, Doroszko A, Niedzielska M, Skarzyńska M, Chybicka A: [Evaluation of selected endocrine complications in patients treated with auto- and allo-haematopoietic stem cell transplantation]. Med Wieku Rozwoj; 2008 Jul-Sep;12(3):761-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of selected endocrine complications in patients treated with auto- and allo-haematopoietic stem cell transplantation].
  • AIM: The aim of this study was to evaluate the endocrine complications, in particular disorders of growth and thyroid function and glucose metabolism dysfunctions in patients treated with allo- and auto-haematopoietic stem cell transplantation (HSCT).
  • MATERIAL AND METHODS: The investigated group consisted of: I. 16 patients after auto-HSCT (6 girls, 10 boys) aged 3-20 years (average 10,8+/-) because of acute myelogenous leukaemia (n=5), non Hodgkin lymphoma (n=3), neuroblastoma (n=3), embryonal cancer (n=2), medulloblastoma (n=1), Ewing's sarcoma/PNET (n=1), hyper eosinophilic syndrome (n=1).
  • Indication for HSCT was acute lymphoblastic leukaemia (n=11), acute myelogenous leukaemia (n=5), chronic myeloid leukaemia-CML (n=6), myelodysplastic syndromes (n=2), non Hodgkin lymphoma (n=1), juvenile myelomonocytic leukemia (n=1), severe aplastic anaemia (n=1), Blackfan-Diamond anaemia (n=1), severe combined immune deficiency (n=1), rhabdomyosarcoma (n=1).
  • [MeSH-major] Endocrine System Diseases / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia / therapy


26. Peñate Y, Guillermo N, Hernández-Machín B, Montenegro T, Borrego L: Cytarabine-associated lymphoid dyscrasia with atypical T CD30+ infiltrate in a patient suffering from acute nonlymphoblastic leukaemia. Br J Dermatol; 2009 May;160(5):1122-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytarabine-associated lymphoid dyscrasia with atypical T CD30+ infiltrate in a patient suffering from acute nonlymphoblastic leukaemia.
  • [MeSH-major] Antigens, CD30 / drug effects. Cytarabine / adverse effects. Immunosuppressive Agents / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Skin Diseases / chemically induced
  • [MeSH-minor] Chronic Disease. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292713.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine
  •  go-up   go-down


27. Zhang ZM, Xie ZX, Tan DR, Huang CH: [Detection of glutathione S-transferase and lung resistance-related proteins in acute leukemia and its clinical significance]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun;30(3):292-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of glutathione S-transferase and lung resistance-related proteins in acute leukemia and its clinical significance].
  • OBJECTIVE: To explore the relationship among intracellular glutathione S-transferase activity (GST), the expression of lung resistance-related proteins (LRP) in acute leukemia, and its clinical effects.
  • METHODS: The GST activity of bone marrow mononuclear cells and LRP expression in 57 acute leukemia patients were detected by the spectrophotometry assay and immuno-cytochemistry (SABC), respectively.
  • RESULTS: The GST activity of bone marrow mononuclear cells in the acute leukemia group was significantly higher than that of the control group (P < 0.01).
  • The GST activity of mononuclear cells in acute leukemia was positively correlated with the percentage of blast in the bone marrow (r = 0.30, P < 0.05).
  • The GST activity of mononuclear cells in the untreated acute leukemia group was obviously higher than that of the complete remission group (P <0.01).
  • The GST activity in the refractory or relapsed acute leukemia group was significantly higher than that of the complete remission group and untreated leukemia group (P <0.05).
  • In post-chemotherapy 13 of 17 the LRP-positive patients were the non-remission, 12 of the 20 LRP-negative patients were the complete remission.
  • The GST activities of non-remission patients in the LRP-positive and LRP-negative group obviously increased.
  • CONCLUSION: The increase of GST activity in the bone marrow mononuclear cells is related to the clinical curative effects and the proliferation of blast in acute leukemia.
  • Detection of LRP and GST activities in acute leukemia may have a reference value in judging the leukemia with drug resistance and estimating the prognosis.
  • [MeSH-major] Glutathione Transferase / metabolism. Leukemia, Myeloid, Acute / metabolism. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / biosynthesis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045016.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


28. Al-Soud YA, Al-Masoudi NA, Loddo R, La Colla P: In-vitro anti-HIV and antitumor activity of new 3,6-disubstituted [1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and thiadiazine analogues. Arch Pharm (Weinheim); 2008 Jun;341(6):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 4-18 were tested in vitro against a panel of tumor cell lines.
  • All compounds are inactive against all the tumor sub-lines, except 10 which exhibited activity against CD4(+) human acute T-lymphoblastic leukaemia of CC(50) = 64 muM.
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Drug Screening Assays, Antitumor. HIV-1 / drug effects. HIV-2 / drug effects. Humans. Structure-Activity Relationship. T-Lymphocytes / drug effects. T-Lymphocytes / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18493972.001).
  • [ISSN] 0365-6233
  • [Journal-full-title] Archiv der Pharmazie
  • [ISO-abbreviation] Arch. Pharm. (Weinheim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents; 0 / Thiadiazines; 0 / Thiadiazoles; 0 / Triazoles
  •  go-up   go-down


29. Piccaluga PP, Rondoni M, Paolini S, Rosti G, Martinelli G, Baccarani M: Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther; 2007 Oct;7(10):1597-611
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of hematologic malignancies has been based for many years on chemotherapy and possibly, for the more aggressive forms, stem cell transplantation.
  • In 2001, the signal transduction inhibitor 571 (STI571, imatinib mesylate) was reported to have striking effects in chronic myeloid leukaemia patients.
  • Since then, imatinib became the first molecular-targeted agent approved for the treatment of human cancer and was later on demonstrated to be effective in other malignancies, such as Philadelphia positive acute lymphoid leukemia, hypereosinophilic syndromes, gastrointestinal stromal tumours and more recently, systemic mastocytosis and other myeloprolipherative disease-carrying platelet-derived growth factor receptor abnormalities.
  • [MeSH-minor] Animals. Benzamides. Drug Interactions. Drug Resistance. Fusion Proteins, bcr-abl / genetics. Fusion Proteins, bcr-abl / metabolism. Humans. Hypereosinophilic Syndrome / drug therapy. Imatinib Mesylate. Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Mastocytosis, Systemic / drug therapy. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / metabolism. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Philadelphia Chromosome. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptors, Platelet-Derived Growth Factor / genetics. Receptors, Platelet-Derived Growth Factor / metabolism. Signal Transduction / drug effects. Treatment Outcome. mRNA Cleavage and Polyadenylation Factors / genetics. mRNA Cleavage and Polyadenylation Factors / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916051.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / FIP1L1-PDGFRA fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / mRNA Cleavage and Polyadenylation Factors; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 92
  •  go-up   go-down


30. Wang HR, Gu CH, Zhu JY, Han JY, Zhong H, Chen FY, Ouyang RR: PNAS-2: a novel gene probably participating in leukemogenesis. Oncology; 2006;71(5-6):423-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: As(4)S(4) is an effective drug for the treatment of acute promyelocytic leukemia but its mechanism of action remains largely unknown.
  • METHODS: NB4 and U937 leukemia cell lines and serial clinical samples were studied.
  • PNAS-2 expression is significantly increased in de novo or relapsed acute leukemia, but in patients in complete remission PNAS-2 levels decrease to levels comparable to those found in normal controls.
  • In carcinomas, PNAS-2 expression was not upregulated, indicating that PNAS-2 overexpression was specific for leukemia.
  • [MeSH-major] Apoptosis / genetics. Apoptosis Regulatory Proteins / genetics. Cell Transformation, Neoplastic / genetics. Leukemia / genetics. Leukemia / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17855796.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / PNAS-2 protein, human; 0 / RNA, Small Interfering
  •  go-up   go-down


31. Ishmael J, Dugard PH: A review of perchloroethylene and rat mononuclear cell leukemia. Regul Toxicol Pharmacol; 2006 Jul;45(2):178-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of perchloroethylene and rat mononuclear cell leukemia.
  • Mononuclear cell leukemia (MNCL) is an extremely common spontaneous disease of ageing F344 rats accompanied by splenomegaly, anemia, thrombocytopenia, and leukemic infiltration (initially of the spleen, liver, and lung).
  • MNCL cells possess natural killer (NK) cell characteristics and apparently, the neoplastic cells derive from large granular lymphocytes (LGL), hence the alternative name of LGL leukemia.
  • LGL leukemia is uncommon in man and occurs in two forms: T-LGL leukemia which has a chronic course, and the much rarer NK-LGL leukemia.
  • In addition to cell type, the latter resembles F344 LGL leukemia being acute in course and involving more pronounced splenomegaly and thrombocytopenia.
  • Chemically related increases in MNCL in F344 rats have not been associated with induction of human LGL leukemia.
  • [MeSH-major] Carcinogens, Environmental / toxicity. Leukemia, Lymphoid / chemically induced. Tetrachloroethylene / toxicity

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. Tetrachloroethylene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16684583.001).
  • [ISSN] 0273-2300
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; TJ904HH8SN / Tetrachloroethylene
  • [Number-of-references] 53
  •  go-up   go-down


32. Schmitt-Graeff A, Hochhaus A: [Hematological side effects of tyrosine kinase inhibition using imatinib]. Pathologe; 2006 Feb;27(1):40-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imatinib (STI571, Gleevec/Glivec) and other small-molecule tyrosine kinase inhibitors are highly effective in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors and, for example, eosinophilia-associated chronic myeloproliferative disorders.
  • Loss of response to imatinib may be due to an acquired resistance of emerging mutant tumor cell clones.
  • However, toxicities including edema, skin rashes, fatigue, nausea and myelosuppression have been reported.
  • Single or multilineage myelodysplasia may be accompanied by an excess of blasts and rarely evolves into acute leukemia in CML patients.
  • [MeSH-minor] Benzamides. Gastrointestinal Diseases / chemically induced. Hematopoiesis / drug effects. Hematopoiesis / genetics. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:132-52 [14633780.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):171-93 [15892618.001]
  • [Cites] Pharmacol Rev. 2003 Sep;55(3):401-23 [12869662.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1941-9 [12411298.001]
  • [Cites] Acta Haematol. 2005;114(1):52-60 [15995325.001]
  • [Cites] Stem Cells. 2005 Sep;23(8):1082-8 [16140870.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):781-4 [16019519.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):237-45 [15101707.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Jun;18(3):641-56, ix [15271397.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):487-97 [15931535.001]
  • [Cites] Blood. 2002 Jul 15;100(2):435-41 [12091333.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Expert Opin Drug Saf. 2005 Mar;4(2):183-91 [15794712.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1340-6 [15190256.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1781-8 [16136600.001]
  • [Cites] Pathologe. 2004 Nov;25(6):428-35 [15179523.001]
  • [Cites] Pathologe. 2004 Mar;25(2):127-34 [15010998.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Oct 1;129(40):2122-7 [15455305.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1659-69 [15747376.001]
  • [Cites] Blood. 2004 Jan 15;103(2):523-9 [12969987.001]
  • [Cites] Blood. 2002 May 15;99(10):3792-800 [11986238.001]
  • [Cites] Leukemia. 2005 Mar;19(3):460-3 [15625554.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:111-35 [12446421.001]
  • [Cites] Blood. 2002 Jan 1;99(1):381-3 [11756197.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):851-3 [15917650.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1573-8 [15990860.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1751-7 [16098458.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1044:168-77 [15958710.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1931-9 [15166033.001]
  • [Cites] Histol Histopathol. 2004 Oct;19(4):1277-88 [15375771.001]
  • [Cites] Blood. 2002 May 15;99(10):3530-9 [11986204.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1163-6 [12921956.001]
  • [Cites] Bone Marrow Transplant. 2005 Sep;36(5):417-24 [16007105.001]
  • (PMID = 16421705.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


33. Bernard N, Devevey L, Jacquemont C, Chrétien P, Helissey P, Guillosson JJ, Arock M, Nafziger J: A new model of pre-B acute lymphoblastic leukemia chemically induced in rats. Exp Hematol; 2005 Oct;33(10):1130-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new model of pre-B acute lymphoblastic leukemia chemically induced in rats.
  • OBJECTIVE: Although B acute lymphoblastic leukemia (B-ALL) is the most common leukemia among children, no chemically inducible model of this leukemia has yet been described in vivo.
  • METHODS: Leukemia was chemically induced in male WKAH/Hkm rats by a nitrosourea derivative, N-butylnitrosourea (BNU), an alkylating agent, administered orally 5 days a week for 24 weeks.
  • Development of leukemia was monitored by clinical observation, follow-up of blood parameters, and appearance of blast cells in peripheral blood samples.
  • The phenotype of the leukemia was determined by cytological examination, cytochemical reactions, and by immunophenotyping of bone marrow cells using various markers.
  • The feasibility of leukemia transplantation was investigated.
  • RESULTS: We observed the appearance of acute leukemia in 60% of the rats treated with BNU.
  • CONCLUSION: This new in vivo model of inducible pre-B-ALL might be useful for investigating the effects of co-initiating or promoting agents suspected to be involved in leukemia development, and for disclosing new molecular events leading to leukemogenic processes.
  • [MeSH-major] Carcinogens / toxicity. Leukemia, Experimental / pathology. Nitrosourea Compounds / toxicity. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Hazardous Substances Data Bank. N-NITROSO-N-BUTYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219535.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosourea Compounds; 869-01-2 / N-nitrosobutylurea
  •  go-up   go-down


34. Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C: Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle; 2008 Apr 15;7(8):1047-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features.
  • The metalloprotease 9 (MMP-9), a known mediator of tumour invasion, is secreted as a 92 kDa pro-form but a non-secreted variant of 85 Kda has been described.
  • We previously showed that the DNA repair protein Ku interacts at the cell surface of leukaemia cell lines with the 85 Kda pro-form of MMP-9 and these Ku/MMP-9 complexes regulates cell invasion, highlighting their importance in haematological malignancies.
  • We demonstrate here that all samples of acute myeloid leukaemia (AML) blasts purified from bone marrow of 16 affected patients express the 85 Kda form of MMP-9.
  • However, only AML that display monocytic lineage markers (AML4/5) express this form at the cell surface with co-expression of the membrane associated form of Ku.
  • Blocking antibodies directed against Ku or MMP-9 specifically inhibited cell invasion of those expressing Ku/MMP-9 on the cell surface.
  • The membrane form of Ku might represent an important factor in the exposition to the cell surface of this specific MMP-9 pro-form in AML with monocytic features.
  • These results might have important functional significance in the occurrence of extra-medullar infiltrates of leukaemia cells that occurs frequently during the onset of monocyte-related AML sub-types.
  • [MeSH-major] DNA Helicases / metabolism. Leukemia, Myeloid, Acute / metabolism. Matrix Metalloproteinase 9 / metabolism. Membrane Proteins / metabolism. Monocytes / metabolism. Neoplasm Invasiveness / physiopathology
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Line, Tumor. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414048.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / XRCC5 protein, human; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.4.- / DNA Helicases
  •  go-up   go-down


35. Claxton DF, Ehmann C, Rybka W: Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol; 2005 Jul;130(2):256-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
  • Non-myeloablative conditioning has extended the use of allogeneic haematopoietic transplant to many previously ineligible patients.
  • A total of 23 patients with acute myelogenous leukaemia (AML) were treated, with a median age of 59 years (range: 28-72) at transplant.
  • Although follow up is short, this data suggests that non-myeloablative haematopoietic cell transplantation with sirolimus (rapamycin)-based immunosuppression may provide disease control over several years in some patients with advanced and poor prognosis AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / administration & dosage. Leukemia, Myeloid, Acute / therapy. Sirolimus / administration & dosage
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chronic Disease. Cyclophosphamide / administration & dosage. Disease Progression. Follow-Up Studies. Graft Survival. Graft vs Host Disease / prevention & control. Humans. Middle Aged. Survival Analysis. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029454.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


36. Dagbashian SS: [Characteristics of respiratory disorders in acute leukemia]. Ter Arkh; 2007;79(12):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of respiratory disorders in acute leukemia].
  • AIM: To characterize respiratory disorders and microflora in patients with acute leukemia (AL).
  • Blast pleurisy was found in 6 patients.
  • [MeSH-major] Leukemia / complications. Respiratory Tract Infections / complications
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Bacteria / isolation & purification. Diagnosis, Differential. Follow-Up Studies. Humans. Middle Aged. Prognosis. Radiography, Thoracic. Retrospective Studies. Sputum / microbiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220035.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


37. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA: Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med; 2010 Feb;16(2):205-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.
  • We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation.
  • We demonstrate that PP242, but not rapamycin, causes death of mouse and human leukemia cells.
  • In vivo, PP242 delays leukemia onset and augments the effects of the current front-line tyrosine kinase inhibitors more effectively than does rapamycin.
  • These findings establish that Ph(+) transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.


38. Cheadle EJ: MT-103 Micromet/MedImmune. Curr Opin Mol Ther; 2006 Feb;8(1):62-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma.
  • The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
  • [MeSH-minor] Animals. Clinical Trials, Phase I as Topic. Humans. Lymphoma, B-Cell / drug therapy. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506527.001).
  • [ISSN] 1464-8431
  • [Journal-full-title] Current opinion in molecular therapeutics
  • [ISO-abbreviation] Curr. Opin. Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 4FR53SIF3A / blinatumomab
  •  go-up   go-down


39. Uzunhan Y, Cadranel J, Boissel N, Gardin C, Arnulf B, Bergeron A: [Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas)]. Rev Mal Respir; 2010 Jun;27(6):599-610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION - BACKGROUND: The non infectious pulmonary manifestations occurring in lymphoplasmocytic proliferations others than lymphomas are poorly understood and have rarely been the object of dedicated publications.
  • We will also consider acute lymphoblastic leukaemia, chronic lymphocytic leukaemia and hairy cell leukaemia, as well as malignant plasmocytic disorders such as myeloma, POEMS syndrome and Waldenström's macroglobulinaemia.
  • CONCLUSION: During the course of lymphoplasmocytic diseases, lung manifestations are variable and sometimes require invasive techniques for definitive diagnosis.
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Multiple Myeloma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Waldenstrom Macroglobulinemia / complications

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
  • (PMID = 20610075.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


40. Laurent S, Palmisano GL, Martelli AM, Kato T, Tazzari PL, Pierri I, Clavio M, Dozin B, Balbi G, Megna M, Morabito A, Lamparelli T, Bacigalupo A, Gobbi M, Pistillo MP: CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. Br J Haematol; 2007 Feb;136(4):597-608
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis.
  • We have previously reported that about 80% of acute myeloid leukaemia (AML) samples tested at diagnosis constitutively expressed cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4).
  • The present study compared CTLA-4 expression and function of leukaemic cells from AML patients at diagnosis with those from AML patients resistant to conventional chemotherapy.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation / metabolism. Antigens, Neoplasm / metabolism. Apoptosis. Leukemia, Myeloid / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367412.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD80; 0 / Antigens, CD86; 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / CD86 protein, human; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Ligands; EC 3.4.22.- / Caspases
  •  go-up   go-down


41. Mony U, Jawad M, Seedhouse C, Russell N, Pallis M: Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. Leukemia; 2008 Jul;22(7):1395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.
  • Relapse in acute myeloid leukaemia (AML) is mediated by survival of leukaemic stem cells following remission-induction chemotherapy.
  • Our data point to a need to investigate more novel chemotherapeutic agents under these stringent conditions to identify agents that may be suitable to target minimal residual disease in AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Neoplastic Stem Cells / drug effects. Tyrphostins / pharmacology. fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
  • [MeSH-minor] Antigens, CD34 / analysis. Antigens, CD38 / analysis. Cell Line, Tumor. Cell Survival / drug effects. Cytarabine / pharmacology. Drug Resistance, Neoplasm. Humans. Interleukin-3 Receptor alpha Subunit / analysis. Membrane Glycoproteins / analysis. Phenotype. Receptors, Interleukin-3 / analysis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18509353.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / IL3RA protein, human; 0 / Interleukin-3 Receptor alpha Subunit; 0 / Membrane Glycoproteins; 0 / Receptors, Interleukin-3; 0 / Tyrphostins; 04079A1RDZ / Cytarabine; 146535-11-7 / 6,7-dimethoxy-3-phenylquinoxaline; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


42. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, Dewald GW, Kantarjian HM, Pierce SR, Estey EH: The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol; 2006 Oct;135(2):165-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.
  • To better understand the spectrum of adult acute myeloid leukaemia (AML) associated with core binding factor (CBF) translocations, 370 patients with newly diagnosed CBF-associated AML were analysed.
  • Patients with t(8;21) tended to be younger (P = 0.056), have lower peripheral blood white cell counts (P < 0.0001) and were more likely to have additional cytogenetic abnormalities (P < 0.0001).
  • Overall, 87% [95% confidence interval (CI) 83-90%] of patients achieved complete response (CR) with no difference between t(8;21) and inv(16); however, the CR rate was lower in older patients due to increased resistant disease and early deaths.
  • Ten-year overall survival (OS) was 44% (95% CI 39-50%) and, in multivariate analysis, was shorter with increasing age (P < 0.0001), increased peripheral blast percentage (P = 0.0006), in patients with complex cytogenetic abnormalities in addition to the CBF translocation (P = 0.021), and in patients with t(8;21) (P = 0.025).
  • OS was superior in patients who received regimens with high-dose cytarabine, a combination of fludarabine and intermediate-dose cytarabine, or haematopoietic cell transplantation.
  • [MeSH-major] Core Binding Factors / genetics. Leukemia, Myeloid / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Female. Hematopoietic Stem Cell Transplantation. Humans. Leukocyte Count. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939487.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA17145; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factors
  •  go-up   go-down


43. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V: Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet; 2010 Dec 11;376(9757):2009-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
  • BACKGROUND: Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static.
  • We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens.
  • Patients aged 1-18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype.
  • After three blocks of therapy, all high-risk group patients and those from the intermediate group with postinduction high minimal residual disease (≥10(-4) cells) received an allogenic stem-cell transplant.
  • Standard-risk and intermediate-risk patients with postinduction low minimal residual disease (<10(-4) cells) continued chemotherapy.
  • Differences in progression-free survival between groups were mainly related to a decrease in disease events (progression, second relapse, disease-related deaths; HR 0·56, 0·34-0·92, p=0·007) rather than an increase in adverse treatment effects (treatment death, second malignancy; HR 0·52, 0·24-1·11, p=0·11).
  • INTERPRETATION: As compared with idarubicin, mitoxantrone conferred a significant benefit in progression-free and overall survival in children with relapsed acute lymphobastic leukaemia, a potentially useful clinical finding that warrants further investigation.
  • FUNDING: Cancer Research UK, Leukaemia and Lymphoma Research, Cancer Council NSW, and Sporting Chance Cancer Foundation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / therapeutic use. Mitoxantrone / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Antibiotics, Antineoplastic / therapeutic use. Asparaginase / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Infant. Kaplan-Meier Estimate. Leukocyte Count. Male. Methotrexate / administration & dosage. Polyethylene Glycols / administration & dosage. Recurrence. Risk Assessment. Treatment Outcome. United Kingdom. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Blood. 2008 Mar 1;111(5):2548-55 [18039957.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5800-7 [18089878.001]
  • [Cites] J Cell Mol Med. 2009 Oct;13(10):4239-56 [19725919.001]
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2339-47 [20385996.001]
  • [Cites] Leukemia. 2010 Feb;24(2):253-4 [20145664.001]
  • [Cites] Leukemia. 2010 Feb;24(2):450-9 [20016529.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):648-54 [19841326.001]
  • [Cites] Cell Mol Immunol. 2009 Dec;6(6):469-75 [20003823.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):453-8 [18928659.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3971-8 [18711187.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2573-80 [18089849.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1013-34 [12764363.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62 [14504921.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18814-23 [14963025.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1495-6 [15494596.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6525-8 [2208112.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] Int J Hematol. 1991 Jun;54(3):219-30 [1747457.001]
  • [Cites] Haematologica. 1997 Nov-Dec;82(6):664-7 [9499665.001]
  • [Cites] N Engl J Med. 1998 Jun 4;338(23):1663-71 [9614257.001]
  • [Cites] Clin Exp Immunol. 2005 Jan;139(1):152-8 [15606626.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):67-78 [15647217.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [CommentIn] Lancet. 2010 Dec 11;376(9757):1968-70 [21131040.001]
  • [CommentIn] Nat Rev Clin Oncol. 2011 Mar;8(3):123 [21480558.001]
  • (PMID = 21131038.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 14840; United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 30IQX730WE / Polyethylene Glycols; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7D96IR0PPM / pegaspargase; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC3010035
  •  go-up   go-down


44. Kan JH, Hernanz-Schulman M, Frangoul HA, Connolly SA: MRI diagnosis of bone marrow relapse in children with ALL. Pediatr Radiol; 2008 Jan;38(1):76-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI diagnosis of bone marrow relapse in children with ALL.
  • BACKGROUND: Diffuse marrow replacement in acute leukemia is well known, but there are few reports describing the MRI features of pediatric leukemic relapse.
  • From this group, 14 children seen at initial diagnosis of leukemia and 2 children who underwent MRI after therapy for relapse were excluded.
  • Images of patients with relapse and in remission were reviewed for type and configuration of marrow infiltration; coexisting marrow alterations including osteonecrosis or stress reaction were also reviewed.
  • CONCLUSION: Well-defined nodules in all patients with leukemic relapse suggest that this appearance is characteristic and distinct from the published findings of diffuse marrow replacement in acute leukemia.
  • [MeSH-major] Bone Marrow Diseases / diagnosis. Magnetic Resonance Imaging / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Paediatr Scand Suppl. 1974;(252):1-20 [4618418.001]
  • [Cites] Acta Paediatr Scand. 1981 Nov;70(6):879-83 [7324941.001]
  • [Cites] J Urol. 1991 Aug;146(2 ( Pt 2)):665-8 [1861322.001]
  • [Cites] Semin Nucl Med. 1992 Apr;22(2):98-111 [1317065.001]
  • [Cites] Acta Paediatr Scand. 1989 Nov;78(6):923-9 [2557721.001]
  • [Cites] Radiology. 1986 Jul;160(1):237-40 [3459212.001]
  • [Cites] Arch Dis Child. 2003 Aug;88(8):688-94 [12876164.001]
  • [Cites] J Urol. 2004 Sep;172(3):1071-3; discussion 1073-4 [15311040.001]
  • [Cites] Pediatr Radiol. 2006 Nov;36(11):1119-32; quiz 1228-9 [16791588.001]
  • [Cites] Pediatrics. 2000 Jun;105(6):1236-41 [10835063.001]
  • [Cites] J Urol. 1988 Nov;140(5 Pt 2):1169-74 [2846898.001]
  • [Cites] J Urol. 1983 Jun;129(6):1102-6 [6343637.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 2):1548-50 [14501657.001]
  • [Cites] J Urol. 1999 Jun;161(6):1928-33 [10332475.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1743-5 [1433600.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):559-63 [8410507.001]
  • [Cites] Radiology. 1991 Nov;181(2):587-9 [1924809.001]
  • [Cites] J Urol. 2004 Sep;172(3):1075-7; discussion 1077 [15311041.001]
  • [Cites] N Z Med J. 1995 Apr 26;108(998):142-4 [7761049.001]
  • [Cites] Pediatr Nephrol. 1993 Aug;7(4):361-4 [8398641.001]
  • [Cites] J Pediatr. 2000 Jan;136(1):30-4 [10636970.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] Arch Dis Child. 1995 May;72 (5):393-6 [7618903.001]
  • [Cites] Radiology. 1998 May;207 (2):377-84 [9577484.001]
  • [Cites] J Urol. 1996 May;155(5):1711-5 [8627867.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 1994 Mar;70(2):F147-9; discussion 149-50 [7802758.001]
  • [Cites] BJU Int. 2000 Jul;86(1):94-6 [10886091.001]
  • [Cites] Nephron. 1982;30(3):262-8 [7099339.001]
  • [Cites] Pediatr Radiol. 1990;20(3):179-83 [2352796.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):941-6 [3656575.001]
  • [Cites] Lancet. 1973 Jul 7;2(7819):1-4 [4123292.001]
  • [Cites] Pediatr Radiol. 1990;20(4):272-6 [2336289.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):279-82 [15224367.001]
  • [Cites] Arch Dis Child. 1991 Nov;66(11):1282-3 [1661570.001]
  • [Cites] J Urol. 1998 Sep;160(3 Pt 2):1019-22 [9719268.001]
  • [Cites] J Urol. 1975 Aug;114(2):274-80 [1171997.001]
  • [Cites] Clin Radiol. 1960 Oct;11:219-31 [13714877.001]
  • [Cites] Pediatr Nephrol. 1997 Feb;11(1):108-20 [9035184.001]
  • [Cites] BMJ. 1994 May 7;308(6938):1193-6 [8180534.001]
  • [Cites] Urology. 1999 Apr;53(4):812-5 [10197863.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Urol. 2006 Oct;176(4 Pt 2):1786-92 [16945650.001]
  • [Cites] J Urol. 2005 Mar;173(3):697-704 [15711246.001]
  • [Cites] Pediatrics. 2006 Mar;117(3):626-32 [16510640.001]
  • [Cites] Clin Nephrol. 1973 May-Jun;1(3):132-41 [4783715.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1674-5 [1433586.001]
  • [Cites] J Urol. 2000 Nov;164(5):1674-8; discussion 1678-9 [11025746.001]
  • [Cites] Br Med J. 1965 Apr 17;1(5441):1023-6 [14262192.001]
  • [Cites] J Urol. 2005 Feb;173(2):571-4; discussion 574-5 [15643259.001]
  • [Cites] Infect Dis Clin North Am. 1987 Dec;1(4):713-29 [3333655.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2002 Feb;32(2):40-9 [11951089.001]
  • [Cites] J Urol. 1976 Oct;116(4):503-5 [1053345.001]
  • [Cites] Radiology. 1991 Jan;178(1):193-6 [1984303.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):163 [15813842.001]
  • [Cites] Pediatrics. 1999 Apr;103(4 Pt 1):843-52 [10103321.001]
  • [Cites] Pediatr Nephrol. 1998 Nov;12 (9):727-36 [9874316.001]
  • [Cites] J Am Soc Nephrol. 2003 Mar;14 (3):739-44 [12595511.001]
  • [Cites] J Pediatr. 1996 Jan;128(1):15-22 [8551409.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1653-6 [1433582.001]
  • [Cites] Pediatr Nephrol. 2006 Jun;21(6):785-92 [16565873.001]
  • (PMID = 17994232.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


45. Parker WB, Shaddix SC, Gilbert KS, Shepherd RV, Waud WR: Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine. Cancer Chemother Pharmacol; 2009 Jul;64(2):253-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1-beta-D-[4-thio-arabinofuranosyl] cytosine (T-araC) is a new cytosine analog that has exhibited excellent activity against a broad spectrum of human solid tumors and leukemia/lymphoma xenografts in mice and is currently being evaluated in patients as a new drug for the treatment of cancer.
  • RESULTS: Initial studies with various tumor cells in culture indicated that a 2-h incubation with clofarabine enhanced the metabolism of T-araC 24 h after its removal by threefold in three tumor cell types (HCT-116 colon, K562 leukemia, and RL lymphoma) and by 1.5-fold in two other tumor cell types (MDA-MB-435 breast (melanoma), and HL-60 leukemia).
  • Pretreatment with clofarabine resulted in a slight decrease in metabolism of T-araC in RPMI-8226 myeloma cells (65% of control) and inhibited metabolism of T-araC in CCRF-CEM leukemia cells by 90%.
  • CONCLUSIONS: These studies provide a rationale for clinical trials using this combination in the treatment of acute leukemias as well as solid tumors and suggest that this combination would exhibit greater antitumor activity than that of clofarabine plus araC.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / pharmacology. Arabinonucleosides / therapeutic use. Neoplasms, Experimental / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19002461.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA34200
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 4'-thio-arabinofuranosylcytosine; 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


46. Nowicki M, Ostalska-Nowicka D, Kaczmarek E, Miskowiak B, Witt M: Vascular endothelial growth factor C--a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach. Histopathology; 2006 Aug;49(2):170-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor C--a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach.
  • AIMS: To investigate the immunocytochemical expression of vascular endothelial growth factor C (VEGF-C) and its receptors (VEGFR-2 and VEGFR-3) in childhood acute lymphoblastic leukaemia (ALL) blasts and to determine the possible role of this complex in the pathogenesis and prognosis of ALL.
  • CONCLUSIONS: The absence of VEGF-C in blast cells predicts long-lasting remission in all leukaemic children.
  • Our findings also suggest that leukaemic cell invasion, following VEGF-C-driven lymphangiogenesis, could be related to a mediating role of this peptide produced by blast cells themselves.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Vascular Endothelial Growth Factor C / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879394.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


47. Sandoval C, Pine SR, Guo Q, Sastry S, Stewart J, Kronn D, Jayabose S: Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer; 2005 Jan;44(1):85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
  • Infants with constitutional trisomy 21 are at increased risk of developing transient and acute megakaryoblastic leukemia (AMKL).
  • Mutations in GATA1 have been identified in trisomy 21 patients with AMKL, and this lesion is thought to be an initial event by virtue of its presence during transient leukemia.
  • Transient leukemia is also observed in phenotypically normal infants albeit much less commonly so.
  • Almost all these infants are mosaic for trisomy 21, and the clinical course of transient leukemia recapitulates that observed in constitutional trisomy 21.
  • We report a phenotypically normal infant with tetrasomy 21 transient leukemia, GATA1 mutation within exon 2, and trisomy 21 mosaicism restricted to the hematopoietic tissue.
  • Two years after diagnosis, low levels of trisomy 21 persisted in the peripheral blood, which resolved 2.5 years after diagnosis.
  • The literature review identified 32 phenotypically normal infants with transient leukemia.
  • Ninety-one percent (29 of 32) were observed and three received chemotherapy at diagnosis of transient leukemia.
  • Nineteen percent (6 of 32) developed acute leukemia, and four continued in remission (two died).
  • Transient leukemia in trisomy 21 mosaicism recapitulates the condition observed in constitutional trisomy 21 at the biological and clinical levels.
  • Infants should be followed for the development of acute leukemia.
  • [MeSH-major] DNA-Binding Proteins / genetics. Down Syndrome / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for tetrasomy 21 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15390279.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Erythroid-Specific DNA-Binding Factors; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 46
  •  go-up   go-down


48. Prata C, Maraldi T, Fiorentini D, Zambonin L, Hakim G, Landi L: Nox-generated ROS modulate glucose uptake in a leukaemic cell line. Free Radic Res; 2008 May;42(5):405-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nox-generated ROS modulate glucose uptake in a leukaemic cell line.
  • The discovery of superoxide-generating enzymes homologues of phagocytic NAD(P)H oxidase, the Nox family, has led to the concept that reactive oxygen species (ROS) are 'intentionally' generated with biological functions in various cell types.
  • In this study, by treating an acute leukaemic cell line with different antioxidants, ROS generation was shown to be crucially involved in the modulation of glucose transport (mediated by Glut1), which is frequently up-regulated in cancer cells.
  • On the whole, data suggest that both Glut1 and Nox homologues may be considered new potential targets in the treatment of leukaemia.
  • [MeSH-major] Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Leukemic. Glucose / pharmacokinetics. Leukemia / therapy. Membrane Glycoproteins / metabolism. NADPH Oxidase / metabolism. Reactive Oxygen Species
  • [MeSH-minor] Antioxidants / metabolism. Biological Transport. Cell Line, Tumor. Glucose Transporter Type 1 / metabolism. Humans. Phosphorylation. Protein Isoforms. Protein-Tyrosine Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473264.001).
  • [ISSN] 1029-2470
  • [Journal-full-title] Free radical research
  • [ISO-abbreviation] Free Radic. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / CYBB protein, human; 0 / Glucose Transporter Type 1; 0 / Membrane Glycoproteins; 0 / Protein Isoforms; 0 / Reactive Oxygen Species; 0 / SLC2A1 protein, human; EC 1.6.3.- / NOX4 protein, human; EC 1.6.3.1 / NADPH Oxidase; EC 2.7.10.1 / Protein-Tyrosine Kinases; IY9XDZ35W2 / Glucose
  •  go-up   go-down


49. Olesen KM, Hansen SH, Sidenius U, Schmiegelow K: Determination of leukocyte DNA 6-thioguanine nucleotide levels by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar 15;864(1-2):149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a small cohort of eight children with acute lymphoblastic leukaemia (ALL), a median of one 6-thioguanine base was found for each 3000 normal bases (range 1:2000-1:11000).
  • [MeSH-minor] Child. Chromatography, Affinity. Chromatography, High Pressure Liquid / methods. Humans. Hydrogen-Ion Concentration. Hydrolysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Quality Control. Reproducibility of Results. Sensitivity and Specificity. Thioguanine / analogs & derivatives. Thioguanine / analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOGUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313997.001).
  • [ISSN] 1570-0232
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Guanine Nucleotides; 0 / N2,3-etheno-6-thioguanine; 0 / Thionucleotides; 15867-02-4 / 6-thioguanylic acid; 9007-49-2 / DNA; FTK8U1GZNX / Thioguanine
  •  go-up   go-down


50. Ly-Sunnaram B, Henry C, Gandemer V, Mee FL, Burtin F, Blayau M, Cayuela JM, Oster M, Clech P, Rambeau M, Marie C, Pampin C, Edan C, Gall EL, Goasguen JE: Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis. Leuk Res; 2005 Sep;29(9):1089-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe here a late extramedullary ovarian relapse in an 18-year-old female who was diagnosed with hypotetraploid cell acute lymphoblastic leukaemia (cALL) at the age of 6.
  • At both occurrences of the disease cells were analyzed by morphology, immunophenotyping, cytogenetics and molecular methods.
  • Moreover, interphasic FISH using TEL and AML1 probes showed the loss of a second TEL at the time of relapse.
  • [MeSH-major] Gene Deletion. Oncogene Proteins, Fusion / genetics. Ovarian Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038737.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


51. Stussi G, Tichelli A, Schanz U, Goede J: Hypereosinophilia with a low blast count as the initial manifestation of acute myeloid leukaemia with RUNX1-RUNX1T1. Br J Haematol; 2009 Aug;146(4):346
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypereosinophilia with a low blast count as the initial manifestation of acute myeloid leukaemia with RUNX1-RUNX1T1.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Hypereosinophilic Syndrome / genetics. Leukemia, Myeloid, Acute / genetics. Oncogene Proteins, Fusion / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388941.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


52. Semsei AF, Erdélyi DJ, Ungvári I, Kámory E, Csókay B, Andrikovics H, Tordai A, Cságoly E, Falus A, Kovács GT, Szalai C: Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res; 2008 Aug;32(8):1214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia.
  • To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.
  • [MeSH-major] P-Glycoprotein / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2008 Aug;32(8):1173-5 [18294687.001]
  • (PMID = 18243305.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


53. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L: Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia; 2006 Mar;8(3):223-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages.
  • Assay of these molecules by enzyme-linked immunosorbent assay in patients suffering from another hematologic disorder (acute leukemia) highlights increased sHLA-G secretion.
  • This increased secretion seems more marked in acute leukemia subtypes affecting monocytic and lymphoid lineages such as FABM4 and FABM5, as well as both B and T acute lymphoblastic leukemia (ALL).
  • All these findings suggest that sHLA-G molecules could be a factor in tumoral escape from immune survey during acute leukemia.
  • [MeSH-major] Antigens, Neoplasm / blood. HLA Antigens / blood. Histocompatibility Antigens Class I / blood. Leukemia / blood
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / chemistry. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cytokines / blood. Cytokines / pharmacology. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Leukemic / drug effects. HLA-G Antigens. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / classification. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Retrospective Studies. Solubility. Tumor Escape

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jun 15;164(12):6100-4 [10843658.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):379-85 [14708718.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):280-2 [11091213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1102-7 [11137213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1138-49 [11137219.001]
  • [Cites] Hum Immunol. 2000 Dec;61(12):1347-51 [11163092.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6133-9 [11087747.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):369-76 [11466692.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12150-5 [11572934.001]
  • [Cites] Nephrologie. 2003;24(8):451-6 [14737978.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9145-9 [3480534.001]
  • [Cites] Science. 1990 Apr 13;248(4952):220-3 [2326636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3947-51 [1570318.001]
  • [Cites] Cell Immunol. 1994 May;155(2):312-22 [8181068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4209-13 [8183892.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5516-24 [7989753.001]
  • [Cites] Tissue Antigens. 1996 Nov;48(5):609-14 [8988550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5249-54 [9144223.001]
  • [Cites] J Exp Med. 1997 Jul 21;186(2):289-98 [9221758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11520-5 [9326642.001]
  • [Cites] Eur J Immunol. 1997 Dec;27(12):3380-8 [9464826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1980-90 [9645380.001]
  • [Cites] Hum Immunol. 1998 Aug;59(8):524-8 [9712358.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):277-83 [9933109.001]
  • [Cites] Tissue Antigens. 1999 Jan;53(1):14-22 [10082427.001]
  • [Cites] Int Immunol. 1999 May;11(5):803-11 [10330285.001]
  • [Cites] Am J Reprod Immunol. 1999 Jul;42(1):30-6 [10429764.001]
  • [Cites] J Reprod Immunol. 1999 Jul;43(2):105-9 [10479047.001]
  • [Cites] Autoimmun Rev. 2005 Nov;4(8):503-9 [16214086.001]
  • [Cites] Hum Immunol. 2005 Aug;66(8):853-63 [16216668.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4772-80 [11971028.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3576-86 [12516543.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1191-6 [12552087.001]
  • [Cites] Eur J Immunol. 2003 Jan;33(1):125-34 [12594841.001]
  • [Cites] Leuk Res. 2003 Jul;27(7):643-8 [12681364.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):752-61 [12878353.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):802-10 [12878359.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1017-24 [14602230.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1093-101 [14602240.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):606-11 [14697234.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):343-51 [14708714.001]
  • [Cites] Ann Neurol. 2000 Oct;48(4):679-84 [11026456.001]
  • (PMID = 16611416.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC1578523
  •  go-up   go-down


54. Labrou NE, Papageorgiou AC, Avramis VI: Structure-function relationships and clinical applications of L-asparaginases. Curr Med Chem; 2010;17(20):2183-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • L-asparaginase (L-ASNase, EC 3.5.1.1) catalyzes the hydrolysis of the non-essential amino acid L-Asn to LAsp and ammonia and is widely used for the treatment of haematopoetic diseases such as acute lymphoblastic leukaemia (ALL) and lymphomas.
  • [MeSH-minor] Catalytic Domain. Clinical Trials as Topic. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Engineering. Protein Structure, Tertiary. Structure-Activity Relationship

  • BioCyc. gene/protein/disease-specific - ansB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423302.001).
  • [ISSN] 1875-533X
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


55. Köhler K, Regner A, Koenigsmann M, Franke A, Frommer J: [Illness perceptions of patients suffering from acute leukaemia one week after diagnosis]. Z Psychosom Med Psychother; 2005;51(4):388-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Illness perceptions of patients suffering from acute leukaemia one week after diagnosis].
  • OBJECTIVES: To investigate illness perceptions, treatment expectations, and treatment experiences of patients suffering from acute leukaemia in the initial stage of their disease.
  • METHODS: In the first week of treatment we interviewed twelve patients with acute leukaemia using a detailed semi-structured interview guide.
  • [MeSH-major] Leukemia, Myeloid, Acute / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Sick Role

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402336.001).
  • [ISSN] 1438-3608
  • [Journal-full-title] Zeitschrift für Psychosomatische Medizin und Psychotherapie
  • [ISO-abbreviation] Z Psychosom Med Psychother
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Li XL, Sun LR: [Effect of muramyl dipeptide on proliferation of dendritic cells derived from children acute leukemia bone marrow in vitro]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug;18(4):963-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of muramyl dipeptide on proliferation of dendritic cells derived from children acute leukemia bone marrow in vitro].
  • The aim of this study was to explore the effect of muramyl dipeptide (MDP) on proliferation of dendritic cells (DCs) from bone marrow of children with acute leukemia in vitro.
  • The mononuclear cells were isolated from bone marrow of children with acute leukemia to induce dendritic cells.
  • It is concluded that MDP not only promotes the proliferation of DCs derived from bone marrow of children with acute leukemia in vitro, cooperates with rhGM-CSF, rhIL-4 and rhTNFalpha in promoting of the proliferation and maturation of DCs, while the promotive effect of MDP alone on the proliferation of DCs is not as good as its combination with cytokines.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723309.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 53678-77-6 / Acetylmuramyl-Alanyl-Isoglutamine
  •  go-up   go-down


57. Latagliata R, Breccia M, Fazi P, Iacobelli S, Martinelli G, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F: Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol; 2008 Dec;143(5):681-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
  • This randomized phase III clinical trial explored the efficacy of DaunoXome (DNX) versus Daunorubicin (DNR) in acute myeloid leukaemia (AML) patients aged >60 years.
  • After CR, DNX showed a higher incidence of early deaths (12.5% vs. 2.6% at 6 months, P = 0.053) but a lower incidence of relapse beyond 6 months (59% vs. 78% at 24 months, P = 0.064), with a cross in overall survival (OS) and disease-free survival (DFS) curves and a later advantage for DNX arm after 12 months from diagnosis.
  • DNX seems to improve OS and DFS in the long-term follow-up, because of a reduction in late relapses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Daunorubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Liposomes. Male. Middle Aged. Proportional Hazards Models. Recurrence. Remission Induction / methods. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18950458.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


58. Agarwal R, Gupta R, Bakhshi S, Sharma A: Unusual cytochemical reactivity for toluidine blue in granular acute lymphoblastic leukemia: a report of two rare cases. Turk J Haematol; 2010 Mar 5;27(1):43-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual cytochemical reactivity for toluidine blue in granular acute lymphoblastic leukemia: a report of two rare cases.
  • [Transliterated title] Granüler akut lenfoblastik lösemide toluidin mavisine yönelik olağandışı sitokimyasal reaktivite: İki nadir olgu raporu.
  • Azurophilic granulation of blasts is a feature of acute myeloid leukemia (AML).
  • Granular acute lymphoblastic leukemia (ALL) may mimic AML due to the presence of cytoplasmic granules in lymphoblasts, but cytochemistry and immunophenotyping are helpful in making the correct diagnosis.
  • Immunophenotyping and cytogenetic studies were helpful in making a correct diagnosis.
  • This report of two rare case highlight the reactivity of lymphoblasts with TB not hitherto described and the importance of a detailed diagnostic work-up in acute leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265798.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


59. Ma SL, Sørensen AB, Kunder S, Sørensen KD, Quintanilla-Martinez L, Morris DW, Schmidt J, Pedersen FS: The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus. Virology; 2006 Sep 1;352(2):306-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus.
  • ICSBP (interferon consensus sequence binding protein)/IRF8 (interferon regulatory factor 8) is an interferon gamma-inducible transcription factor expressed predominantly in hematopoietic cells, and down-regulation of this factor has been observed in chronic myelogenous leukemia and acute myeloid leukemia in man.
  • By screening about 1200 murine leukemia virus (MLV)-induced lymphomas, we found proviral insertions at the Icsbp locus in 14 tumors, 13 of which were mature B-cell lymphomas or plasmacytomas.
  • Only one was a T-cell lymphoma, although such tumors constituted about half of the samples screened.
  • Interestingly, proviral insertions at Icsbp have not been reported from previous extensive screenings of mature B-cell lymphomas induced by endogenous MLvs. We propose that ICSBP might be involved in an early modulation of an immune response to exogenous MLVs that might also play a role in proliferation of the mature B-cell lymphomas.
  • [MeSH-major] Interferon Regulatory Factors / genetics. Leukemia Virus, Murine / genetics. Leukemia Virus, Murine / pathogenicity. Lymphoma, B-Cell / virology. Plasmacytoma / virology. Virus Integration / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780917.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / interferon regulatory factor-8
  •  go-up   go-down


60. Van Belle W, Anensen N, Haaland I, Bruserud Ø, Høgda KA, Gjertsen BT: Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics; 2006;7:198
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This often proves time consuming and difficult when working with non-perfect gels.
  • Since p53 is altered through these signaling networks, we expected to find correlations between the cancer type (acute lymphoblastic leukemia and acute myeloid leukemia) and the p53 profiles.
  • A second correlation analysis revealed a more complex relation between the differentiation stage in acute myeloid leukemia and p53 protein isoforms.
  • [MeSH-major] Biomarkers, Tumor / analysis. Electrophoresis, Gel, Two-Dimensional / methods. Gene Expression Profiling / methods. Leukemia / metabolism. Neoplasm Proteins / analysis. Protein Processing, Post-Translational. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Electrophoresis. 2005 Jun;26(12):2461-9 [15924363.001]
  • [Cites] Eur J Haematol. 2001 Mar;66(3):178-87 [11350486.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Jun;11(3):469-81 [12183832.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):226-32 [12634796.001]
  • [Cites] Haematologica. 2003 Apr;88(4):416-28 [12681969.001]
  • [Cites] Expert Rev Mol Diagn. 2003 Jul;3(4):411-20 [12877381.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1605-12 [12886250.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Trends Mol Med. 2004 Mar;10(3):113-8 [15102353.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):511-6 [15157174.001]
  • [Cites] Scand J Immunol. 2004 Jul-Aug;60(1-2):189-98 [15238089.001]
  • [Cites] Cell. 2004 Jul 23;118(2):217-28 [15260991.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6887-96 [15501966.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] J Biol Chem. 1979 Aug 25;254(16):7961-77 [468801.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Oct;80(19):5919-22 [6351070.001]
  • [Cites] Br J Haematol. 1991 Jul;78(3):325-9 [1651754.001]
  • [Cites] Electrophoresis. 1991 Oct;12(10):722-35 [1802690.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2230-7 [8161788.001]
  • [Cites] Electrophoresis. 1995 Mar;16(3):298-305 [7607160.001]
  • [Cites] J Biol Chem. 1995 Sep 1;270(35):20599-607 [7657638.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Br J Haematol. 1996 Mar;92(4):929-36 [8616087.001]
  • [Cites] Cell Signal. 1998 Mar;10(3):159-66 [9607138.001]
  • [Cites] Br J Cancer. 1998 May;77(9):1429-38 [9652758.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:98-117 [15561679.001]
  • [Cites] Proteomics. 2004 Dec;4(12):3665-85 [15543535.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):165-71 [15619621.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Haematologica. 2005 Jul;90(7):949-68 [15996933.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):233-48 [16029452.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5386-403 [15983388.001]
  • [Cites] Genes Dev. 2005 Sep 15;19(18):2122-37 [16131611.001]
  • [Cites] Curr Drug Targets. 2005 Sep;6(6):631-46 [16178797.001]
  • [Cites] Electrophoresis. 2006 Oct;27(20):4086-95 [16983632.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1292-300 [10914555.001]
  • (PMID = 16606449.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1559651
  •  go-up   go-down


61. Ragu C, Boukour S, Elain G, Wagner-Ballon O, Raslova H, Debili N, Olson EN, Daegelen D, Vainchenker W, Bernard OA, Penard-Lacronique V: The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development. Leukemia; 2010 Jun;24(6):1227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / pathology. Megakaryocytes / cytology. Megakaryocytes / metabolism. Serum Response Factor / physiology. Trans-Activators / physiology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428204.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MKL1 protein, mouse; 0 / Serum Response Factor; 0 / Trans-Activators; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


62. Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G: Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med (Berl); 2007 Oct;85(10):1069-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.
  • The treatment of cancer by chemotherapy causes tumour cell death, mostly by apoptosis.
  • This tumour cell death may or may not elicit an immune response.
  • At least in some cases, the efficacy of chemotherapy critically depends on the induction of immunogenic cell death that is a type of cell demise that stimulates the activation of an adaptative anti-tumour immune response, which in turn helps to eradicate residual cancer (stem) cells.
  • Indeed, anthracyclins care more efficient in curing tumours in immunocompetent than in T cell-deficient mice.
  • The molecular mechanism implicated in this anti-tumour T cell activation was recently discovered.
  • Anthracyclins cause immunogenic cell death due to their specific capacity to stimulate the translocation of calreticulin to the cell surface.
  • Importantly, non-immunogenic chemotherapy can be rendered immunogenic by adsorbing recombinant calreticulin to tumour cells or by enforcing the translocation of endogenous calreticulin to the cell surface by means of PP1/GADD34 inhibitors.
  • Indeed, in vivo treatments with anthracyclins can cause the translocation of calreticulin to the surface of circulating tumour cells, in patients with acute myeloid leukaemia (AML).
  • The challenge will be to determine whether the exposure of calreticulin translocation on the tumour cell surface is linked to chemotherapy-induced anti-tumour immune responses and therapeutic efficacy in human cancer.
  • [MeSH-minor] Animals. Anthracyclines / pharmacology. Anthracyclines / therapeutic use. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / immunology. Cell Membrane / metabolism. Dendritic Cells / immunology. Humans. Mice. Models, Biological. Neoplasms, Experimental / immunology. T-Lymphocytes, Cytotoxic / immunology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2004 Aug;53(8):740-7 [15133630.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):4853-60 [11673489.001]
  • [Cites] Cell. 2003 Oct 3;115(1):13-23 [14531999.001]
  • [Cites] PLoS Biol. 2005 Jun;3(6):e185 [15839733.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4109-17 [16931630.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1749-54 [15920008.001]
  • [Cites] Int Rev Cytol. 2005;245:91-121 [16125546.001]
  • [Cites] Nat Cell Biol. 2001 Nov;3(11):E255-63 [11715037.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2185-90 [10681453.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):411-6 [10662786.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):205-11 [12455034.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):781-95 [11560994.001]
  • [Cites] Nat Med. 2005 Jul;11(7):725-30 [16015365.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2705-11 [15087383.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5589-95 [12023355.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:281-92 [10567207.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1653-61 [17145602.001]
  • [Cites] Adv Immunol. 2004;84:131-79 [15246252.001]
  • [Cites] Lancet Oncol. 2007 Jan;8(1):2-3 [17196504.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):277-88 [12001989.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Immunol. 2006 Sep 15;177(6):3582-9 [16951317.001]
  • [Cites] J Transl Med. 2005 Feb 21;3(1):9 [15723705.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Immunol Rev. 2006 Dec;214:229-38 [17100888.001]
  • [Cites] Nature. 2005 Sep 29;437(7059):754-8 [16193055.001]
  • [Cites] Exp Hematol. 2005 Feb;33(2):212-8 [15676215.001]
  • [Cites] Nat Med. 2007 Jan;13(1):54-61 [17187072.001]
  • [Cites] Cell. 2005 Oct 21;123(2):321-34 [16239148.001]
  • [Cites] Mol Cell. 2004 May 7;14(3):277-87 [15125832.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):957-62 [11581295.001]
  • [Cites] Science. 2002 Apr 12;296(5566):301-5 [11951032.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2722-9 [16493027.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):375-86 [17256056.001]
  • [Cites] Immunity. 1996 Aug;5(2):103-14 [8769474.001]
  • [Cites] Cancer Immunol Immunother. 2007 Sep;56(9):1485-99 [17285289.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:143-50 [16304372.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2624-31 [16989012.001]
  • [Cites] Clin Breast Cancer. 2006 Jun;7(2):176-9 [16800982.001]
  • [Cites] Nature. 1998 Mar 5;392(6671):86-9 [9510252.001]
  • [Cites] Cell. 1997 Feb 21;88(4):439-43 [9038335.001]
  • [Cites] J Urol. 2007 Jan;177(1):353-8 [17162090.001]
  • [Cites] Science. 2004 May 21;304(5674):1147-50 [15155946.001]
  • [Cites] Int J Cancer. 1988 Dec 15;42(6):883-6 [3263952.001]
  • [Cites] Cancer Immunol Immunother. 2007 May;56(5):641-8 [16960692.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1012-22 [15240689.001]
  • [Cites] Trends Cell Biol. 2001 Mar;11(3):122-9 [11306273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6092-7 [15079077.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jun;56(6):905-11 [17106715.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53 [17255288.001]
  • [Cites] PLoS One. 2006 Dec 27;1:e129 [17205133.001]
  • [Cites] J Exp Med. 2002 Oct 21;196(8):1091-7 [12391020.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):459-67 [15302904.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1884-9 [11912169.001]
  • [Cites] Eur J Immunol. 2004 Feb;34(2):336-44 [14768038.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jul;54(7):685-93 [15627212.001]
  • [Cites] Adv Exp Med Biol. 2005;560:105-14 [15932026.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):784-8 [11048729.001]
  • [Cites] Exp Cell Res. 2007 Feb 1;313(3):500-10 [17137576.001]
  • [Cites] Immunity. 2004 Nov;21(5):643-53 [15539151.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3978-86 [12244199.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1393-404 [15661897.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1640-7 [15514008.001]
  • [Cites] Immunol Rev. 1999 Dec;172:21-8 [10631934.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2808-15 [15254048.001]
  • [Cites] J Biol Chem. 1974 Feb 10;249(3):974-9 [4272851.001]
  • [Cites] Cancer Immunol Immunother. 2006 Apr;55(4):404-11 [16133112.001]
  • [Cites] J Transl Med. 2005 Mar 02;3(1):10 [15740633.001]
  • [Cites] Trends Immunol. 2006 May;27(5):244-50 [16584921.001]
  • [Cites] Clin Exp Metastasis. 2004;21(3):235-42 [15387373.001]
  • [Cites] Science. 2004 Jul 9;305(5681):197-200 [15247468.001]
  • [Cites] J Exp Med. 2005 Dec 19;202(12):1691-701 [16365148.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3750-6 [11739182.001]
  • [Cites] Nat Rev Immunol. 2005 Apr;5(4):296-306 [15803149.001]
  • (PMID = 17891368.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Antineoplastic Agents; 0 / Calreticulin
  • [Number-of-references] 77
  •  go-up   go-down


63. Masson K, Liu T, Khan R, Sun J, Rönnstrand L: A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival. Br J Haematol; 2009 Jul;146(2):193-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
  • The haematopoietic growth factor receptor Flt3 has been implicated as major cause of transformation in acute myeloid leukaemia.
  • Intracellular signals mediated by wild-type Flt3 are involved in cell differentiation and survival whereas signalling via the mutant Flt3 ITD (internal tandem duplication) promotes enhanced cell growth.
  • Ba/F3 cells were transfected with either the wild-type Flt3 or the ITD, with or without a triple mutation of the Grb2 binding sites, and characterised in terms of proliferation and viability.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Leukemia, Myeloid, Acute / metabolism. STAT5 Transcription Factor / metabolism. Tyrosine / physiology. fms-Like Tyrosine Kinase 3 / physiology
  • [MeSH-minor] Binding Sites. Cell Survival. Cell Transformation, Neoplastic. Humans. Mutation. Phosphorylation. Signal Transduction. Tumor Cells, Cultured


64. Dalle F, Lafon I, L'ollivier C, Ferrant E, Sicard P, Labruère C, Jebrane A, Laubriet A, Vagner O, Caillot D, Bonnin A: A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia. Haematologica; 2008 Apr;93(4):581-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia.
  • We report the result of a prospective study aimed at investigating the dynamics and heterogeneity of C. albicans flora in patients with de novo acute leukemia.
  • DESIGN AND METHODS: Between 2001 and 2003, 66 consecutive adults with newly diagnosed acute leukemia were monitored for Candida colonization.
  • CONCLUSIONS: In patients with de novo acute leukemia, genetic evolution of the colonizing C. albicans flora and selection of variants or replacement of the original strain upon antifungal drug pressure or nosocomial transmission are rare events.
  • [MeSH-major] Candida albicans / genetics. Candidiasis / microbiology. Genome, Fungal. Leukemia / complications. Neutropenia / complications
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antifungal Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Fungal / genetics. Female. Genetic Variation. Genotype. Humans. Immunocompromised Host. Male. Middle Aged. Myeloablative Agonists / adverse effects. Myeloablative Agonists / therapeutic use. Organ Specificity. Patient Isolation. Sampling Studies

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322258.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Myeloablative Agonists
  •  go-up   go-down


65. Li X, Du W, Liu W, Li X, Li H, Huang SA: Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS; 2010 May;118(5):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
  • Multiparameter flow cytometry (MFC) plays a vital role in the detection of minimal residual disease (MRD) and diagnosis of relapse in acute leukemia.
  • However, application of a limited panel of antibodies in MFC leads to high rates of false-negative and false-positive results.
  • Thirteen patients with acute lymphoblastic leukemia (ALL) and 12 patients with acute myeloid leukemia (AML) were immunophenotyped by MFC at diagnosis and at relapse using a comprehensive panel of monoclonal antibodies (McAbs) to 27 antigens and CD45/SSC gating.
  • In 23 of 25 patients (92.3%), changes in at least one of progenitor-associated, myeloid and lymphoid antigens between diagnosis and relapse were observed.
  • Multiple panels of three or more McAbs are likely to be required in the monitoring of MRD and diagnosis of relapse in acute leukemia by MFC.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477810.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm
  •  go-up   go-down


71. Barthwal R, Sharma U, Srivastava N, Jain M, Awasthi P, Kaur M, Barthwal SK, Govil G: Structure of daunomycin complexed to d-TGATCA by two-dimensional nuclear magnetic resonance spectroscopy. Eur J Med Chem; 2006 Jan;41(1):27-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anthracycline antibiotic daunomycin, having four fused rings and an amino sugar, is being used in the treatment of acute leukemia.

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293348.001).
  • [ISSN] 0223-5234
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Protons; 9007-49-2 / DNA; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


72. Milech N, Gottardo NG, Ford J, D'Souza D, Greene WK, Kees UR, Watt PM: MEIS proteins as partners of the TLX1/HOX11 oncoprotein. Leuk Res; 2010 Mar;34(3):358-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant expression of the TLX1/HOX11 proto-oncogene is associated with a significant subset of T-cell acute lymphoblastic leukemias (T-ALL).
  • Since, typically, interactions of HOX and TALE homeodomain proteins are determinant of HOX function, and HOX/MEIS co-expression has been shown to accelerate some leukemias, we systematically examined whether TLX1 interacts with MEIS and PBX proteins.
  • Here, we report that TLX1 and MEIS proteins both interact and are co-expressed in T-ALL, and suggest that co-operation between TLX1 and MEIS proteins may have a significant role in T-cell leukemogenesis.
  • [MeSH-major] Homeodomain Proteins / metabolism. Neoplasm Proteins / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Proto-Oncogene Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Blotting, Western. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Child. Humans. Immunoprecipitation. Reverse Transcriptase Polymerase Chain Reaction. Two-Hybrid System Techniques

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19559479.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MEIS2 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / Transcription Factors; 0 / myeloid ecotropic viral integration site 1 protein; 143275-75-6 / TLX1 protein, human
  •  go-up   go-down


73. Craddock C, Tauro S, Moss P, Grimwade D: Biology and management of relapsed acute myeloid leukaemia. Br J Haematol; 2005 Apr;129(1):18-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and management of relapsed acute myeloid leukaemia.
  • Disease relapse remains the major cause of treatment failure in adults with acute myeloid leukaemia (AML).
  • This reflects both the failure of current salvage regimens and the absence of effective strategies to secure long-term disease-free survival in those patients who achieve a second remission.
  • Recent progress in understanding the pathogenesis of relapsed disease has enabled the identification of a variety of dysregulated molecular pathways and these now provide a rational basis for the design of novel targeted therapies.
  • At the same time, advances in allogeneic stem-cell transplantation have permitted the extension of the curative potential of allografting to patients in whom it was previously contraindicated.
  • As a result, a range of novel drug and transplant therapies has become available in patients with relapsed AML, and it is realistic to anticipate that a co-ordinated assessment of their clinical and biological impact will provide the basis for the design of future, more effective treatments in relapsed disease.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / contraindications. Humans. Immunologic Factors / therapeutic use. Recurrence. Salvage Therapy / methods. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801952.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunologic Factors
  • [Number-of-references] 156
  •  go-up   go-down


74. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G: A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol; 2010 Jul;150(1):72-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
  • HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro.
  • We conducted a two-arm, parallel Phase I trial to investigate two schedules of escalating doses of vorinostat (Schedule A: thrice daily (TID) for 14 d; B: TID for 3 d) in combination with a fixed dose of idarubicin in patients with refractory leukaemia.
  • Of the 41 patients enrolled, 90% had acute myeloid leukaemia, with a median of 3 prior therapies.
  • The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Aug 18;840(2):108-15 [16725386.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1174-82 [16675713.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):1967-74 [16928817.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] J Chemother. 2006 Aug;18(4):415-20 [17024798.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Blood. 2007 Jan 1;109(1):31-9 [16960145.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3884-91 [17679729.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2302-8 [17596541.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1247-52 [17962618.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1060-6 [17962510.001]
  • [Cites] Blood. 2008 Aug 15;112(4):981-9 [18495956.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1698-707 [19223502.001]
  • [Cites] Oncogene. 1999 Nov 25;18(50):7016-25 [10597302.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1210-6 [10922406.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 [10954755.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5712-9 [11126357.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8 [11535817.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):194-202 [11902574.001]
  • [Cites] Clin Pharmacokinet. 2002;41(6):431-44 [12074691.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1331-43 [12094258.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):121-31 [12467229.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6231-42 [13679862.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7291-300 [14612526.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8420-7 [14679005.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Feb;49(2):153-63 [15012975.001]
  • [Cites] Cell Cycle. 2004 May;3(5):534-5 [15020838.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;19(4):296-300 [3036387.001]
  • [Cites] J Biol Chem. 1988 Nov 25;263(33):17724-9 [2846576.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7 [9501205.001]
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Cancer Invest. 2005;23(7):635-42 [16305991.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):166-73 [16330674.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):38-51 [16397526.001]
  • [Cites] Hepatology. 2006 Mar;43(3):425-34 [16583461.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):446-57 [16820090.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):563-8 [16865256.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4628-35 [16899611.001]
  • (PMID = 20456355.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA047904; United States / NCI NIH HHS / CA / 2 UO1 CA062461-15; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / P30 CA47904; United States / NCI NIH HHS / CO / N01-CO-124001; United States / NCI NIH HHS / CA / K12-CA088084; United States / NCI NIH HHS / CA / U01 CA062461
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Histones; 0 / Hydroxamic Acids; 0 / RNA, Messenger; 58IFB293JI / vorinostat; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ NIHMS539349; NLM/ PMC4124904
  •  go-up   go-down


75. Stankovic T, Marston E: Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia. Srp Arh Celok Lek; 2008 Mar-Apr;136(3-4):187-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia.
  • Acute lymphoblastic leukaemia (ALL) is the most common paediatric cancer.
  • Despite cure rates approaching 80%, resistance to treatment and disease relapse remain a significant clinical problem.
  • These microarray studies have shown that genes discriminating between clinically responsive and resistant leukaemias tend to be involved in cellular processes such as regulation of cell cycle, proliferation, and DNA repair.
  • Furthermore, apoptotic resistant leukaemias exhibit abnormal response of NFkB pathway following irradiation and inhibition of this pathway can sensitise leukaemic cells to IR-induced DSBs.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720757.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Serbia
  • [Number-of-references] 60
  •  go-up   go-down


76. Kim SR, Kim HJ, Kim SH: [Clinical utility of fluorescence in-situ hybridization profile test in detecting genetic aberrations in acute leukemia]. Korean J Lab Med; 2009 Oct;29(5):371-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical utility of fluorescence in-situ hybridization profile test in detecting genetic aberrations in acute leukemia].
  • BACKGROUND: Cytogenetic abnormalities are one of the most reliable prognostic factors in acute leukemia.
  • The objective of this study was to investigate the utility of FISH profile analyses in the initial diagnosis of acute leukemia.
  • METHODS: Two hundred and forty one de novo acute leukemia patients diagnosed from January, 2002 to November, 2007 were included.
  • For acute lymphoblastic leukemia profile test, FISH probes for BCR/ABL, TEL/AML1, MLL gene rearrangement and CDKN2A deletion were used.
  • For acute myeloid leukemia profile test, probes for AML1/ETO, MLL and CBFbeta gene rearrangement were used.
  • RESULTS: ALL FISH profile tests revealed additional genetic aberrations not detected by chromosome analysis in 48.6% (67/138) of cases, including those with normal karyotypes or no mitotic cells (37%, 51/138).
  • CONCLUSIONS: FISH analysis as a profile test detected additional genetic aberrations in a significant proportion of acute leukemia, and was effective especially in detecting cryptic translocations, submicroscopic deletions and complex karyotypes.
  • Our study supports the need to incorporate FISH profile test at initial work up in acute leukemia.
  • [MeSH-major] Chromosome Aberrations. In Situ Hybridization, Fluorescence / methods. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Core Binding Factor beta Subunit / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Female. Humans. Infant. Infant, Newborn. Karyotyping. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein / genetics. Proto-Oncogene Proteins c-bcr / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893343.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor beta Subunit; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RUNX1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


77. Ferrara F, Mele G, Palmieri S, Pedata M, Copia C, Riccardi C, Izzo T, Criscuolo C, Musto P: Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia. Hematol Oncol; 2009 Dec;27(4):198-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
  • The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous (iv) busulfan (Bu) and continuous infusion Idarubicin (IDA) as a conditioning regimen to autologous haematopoietic stem cell transplantation (ASCT) in patients with acute myeloid leukaemia (AML).
  • The median interval between diagnosis and ASCT was 4 months.
  • In order to perform a comparison in terms of haematological and non haematological toxicity, a group of 30 patients, who were previously autografted after conditioning with IDA and oral Bu was considered.
  • Selection of factors for a matched pair analysis included median age, percentage of subjects aged over 60 years, median CD34+ cell received, cytogenetic and molecular findings and per cent of secondary AML.
  • A longer follow-up is required to assess a potential advantage in terms of disease free survival (DFS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19475701.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] G1LN9045DK / Busulfan; ZRP63D75JW / Idarubicin
  •  go-up   go-down


78. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Gottschalk SM, Bollard CM, Heslop HE, Brenner MK, Krance RA: The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant; 2010 Sep;16(9):1272-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia.
  • In a retrospective study, we evaluated the cost and cost-effectiveness of allogeneic peripheral blood stem cell transplantation (PBSCT) (n = 30) compared with bone marrow transplantation (BMT) (n = 110) in children with acute leukemia after 1 year of follow-up.
  • Treatment success was defined as disease-free survival at 1 year posttransplantation.
  • For patients at standard risk for disease, the treatment success rate was 57.1% for PBSCT recipients and 80.3% for BMT recipients (P = not significant [NS]).
  • The average total cost per treatment success at 1 year in the standard-risk disease group was $512,294 for PBSCT recipients and $352,885 for BMT recipients (P = NS).
  • For patients with high-risk disease, the treatment success rate was 18.8% for PBSCT recipients and 23.5% for BMT recipients (P = NS).
  • Point estimates of the incremental cost-effectiveness ratio (ICER) indicate that in patients with standard-risk disease, allogeneic BMT had lower costs and greater effectiveness than PBSCT (ICER, -$687,108; 95% confidence interval [CI], $2.4 million to dominated).
  • For patients with high-risk disease, BMT was more effective and more costly, and it had an ICER of $1.69 million (95% CI, $29.7 million to dominated) per additional treatment success.
  • The comparative economic evaluation provides support for BMT in standard-risk patients, but much uncertainty precludes a clear advantage of either treatment option in patients with high-risk disease.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):29-37 [12691140.001]
  • [Cites] Bone Marrow Transplant. 2002 Aug;30(4):243-51 [12203141.001]
  • [Cites] Med Decis Making. 1985 Summer;5(2):157-77 [3831638.001]
  • [Cites] Comput Biomed Res. 1986 Jun;19(3):254-65 [3709122.001]
  • [Cites] N Engl J Med. 1989 Sep 21;321(12):807-12 [2505077.001]
  • [Cites] N Engl J Med. 1991 Apr 11;324(15):1005-11 [1848679.001]
  • [Cites] N Z Med J. 1991 Jul 24;104(916):303-5 [1906588.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1601-7 [1658652.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):277-84 [1350938.001]
  • [Cites] Bone Marrow Transplant. 1993 Nov;12(5):469-75 [7905331.001]
  • [Cites] Lancet. 1995 Jan 7;345(8941):9-13 [7799740.001]
  • [Cites] Annu Rev Med. 1995;46:169-79 [7598453.001]
  • [Cites] Blood. 1995 Aug 1;86(3):1228-34 [7620176.001]
  • [Cites] Bone Marrow Transplant. 1995 Sep;16(3):463-70 [8535321.001]
  • [Cites] Lancet. 1996 Feb 10;347(8998):353-7 [8598700.001]
  • [Cites] Nat Med. 1996 May;2(5):551-5 [8616714.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1413-20 [8622054.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3634-41 [8896434.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):275-81 [9028558.001]
  • [Cites] Lancet. 1997 Sep 13;350(9080):767-71 [9297996.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4047-52 [9834208.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(12):1199-205 [9894724.001]
  • [Cites] Bone Marrow Transplant. 1999 Sep;24(5):555-60 [10482942.001]
  • [Cites] Value Health. 2007 Jul-Aug;10(4):247-55 [17645679.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 May;15(5):564-73 [19361748.001]
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):269-73 [10967564.001]
  • [Cites] Curr Opin Hematol. 2000 Nov;7(6):353-7 [11055508.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):689-92 [11360107.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(8):777-83 [11477433.001]
  • [Cites] Blood. 2001 Nov 15;98(10):2900-8 [11698269.001]
  • [Cites] Curr Opin Oncol. 2002 Mar;14(2):160-4 [11880705.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • (PMID = 20348004.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125123-01; United States / NCI NIH HHS / CA / P30 CA125123; United States / NCI NIH HHS / CA / P30 CA 125123; United States / NCI NIH HHS / CA / P30 CA125123-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS207886; NLM/ PMC2919628
  •  go-up   go-down


79. Clavio M, Ghiso A, Ghiggi C, Spriano M, Colombo N, Grasso R, Varaldo R, Miglino M, Pierri I, Olcese F, Aquino S, Biasco S, Balleari E, Carella AM, Sessarego M, Gobbi M: Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa. Oncol Rep; 2009 Apr;21(4):1045-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seventeen years of experience with ATRA-based therapy for acute promyelocytic leukaemia: long-term follow-up of patients treated at S. Martino Hospital, Genoa.
  • We conducted a long-term follow-up retrospective study on 91 consecutive newly diagnosed acute promyelocytic leukaemia (APL) patients.
  • Seventy-eight percent of the patients were expected to be alive at 14 years from diagnosis, i.e., 90 and 48% of patients of intermediate-low risk and high risk at presentation, respectively (p=0.0009).
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288007.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


80. Thachil J: Reduced elimination of Methotrexate in an adult with trisomy 21 and acute lymphoblastic leukaemia. Leuk Res; 2007 Oct;31(10):1452-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced elimination of Methotrexate in an adult with trisomy 21 and acute lymphoblastic leukaemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / blood. Down Syndrome / metabolism. Methotrexate / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178159.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


81. Williams DC Jr, Massey GV, Russell EC, Riley RS, Ben-Ezra J: Translocation-positive acute myeloid leukemia associated with valproic acid therapy. Pediatr Blood Cancer; 2008 Mar;50(3):641-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation-positive acute myeloid leukemia associated with valproic acid therapy.
  • Valproic acid is an effective anti-epileptic medication often used for long-term control of seizure disorders that has been implicated in hematological toxicities, including rare reports of myelodysplasia and acute leukemia.
  • Here, we report a case of valproic acid-related leukemia-like syndrome with a t(8;16) chromosomal translocation.
  • [MeSH-major] Anticonvulsants / adverse effects. Chromosomes, Human, Pair 16 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Leukemia, Myeloid / chemically induced. Translocation, Genetic. Valproic Acid / adverse effects
  • [MeSH-minor] Acute Disease. Cell Differentiation. Cell Division / drug effects. Child, Preschool. Clone Cells / drug effects. Clone Cells / ultrastructure. Cocarcinogenesis. Drug Therapy, Combination. Epilepsy, Absence / drug therapy. Female. Humans. Isoxazoles / administration & dosage. Isoxazoles / therapeutic use. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / ultrastructure. Oncogene Proteins, Fusion / genetics. Phenobarbital / administration & dosage. Phenobarbital / therapeutic use. Piracetam / administration & dosage. Piracetam / analogs & derivatives. Piracetam / therapeutic use. Triazines / administration & dosage. Triazines / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Phenobarbital .
  • Hazardous Substances Data Bank. ZONISAMIDE .
  • Hazardous Substances Data Bank. PIRACETAM .
  • Hazardous Substances Data Bank. LAMOTRIGINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17262798.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / CBP-MOZ fusion protein, human; 0 / Isoxazoles; 0 / Oncogene Proteins, Fusion; 0 / Triazines; 230447L0GL / etiracetam; 459384H98V / zonisamide; 614OI1Z5WI / Valproic Acid; U3H27498KS / lamotrigine; YQE403BP4D / Phenobarbital; ZH516LNZ10 / Piracetam
  •  go-up   go-down


82. Gallipoli P, Drummond MW: Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia. Eur J Haematol; 2009 Mar;82(3):242-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Pseudotumor Cerebri / chemically induced. Pseudotumor Cerebri / therapy. Tretinoin / adverse effects. Tretinoin / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Haematol. 2009 May;82(5):411. Drummond, M W [added]
  • (PMID = 19018859.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


83. Abdallah E, Hajji Z, Mellal Z, Belmekki M, Bencherifa F, Berraho A: [Macular serous detachment revealing acute lymphoblastic leukemia]. J Fr Ophtalmol; 2005 Jan;28(1):39-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Macular serous detachment revealing acute lymphoblastic leukemia].
  • BACKGROUND: Leukemias are a group of malignant diseases caused by immature hematopoietic cells proliferating in the blood marrow.
  • OBSERVATION: We report a case of a 42-year-old women presenting with loss of vision caused by serous macular detachment.
  • The investigations showed the diagnosis of acute lymphoblastic leukemia.
  • DISCUSSION: Ocular involvement is seen in 28%-80% of leukemia cases.
  • Serous detachment of the neuroepithelium is seldom reported, and can be the first symptom of the disease.
  • CONCLUSION: Ocular manifestations of leukemia are frequent but rarely reveal the disease.
  • However, the diagnosis of leukemia should be considered in case of pigmentary epithelium involvement.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Retinal Detachment.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767897.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


84. Bonnet D: Cancer stem cells: AMLs show the way. Biochem Soc Trans; 2005 Dec;33(Pt 6):1531-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The blood-related cancer leukaemia was the first disease where human CSCs (cancer stem cells), or LSCs (leukaemic stem cells), were isolated.
  • Leukaemia can now be viewed as aberrant haematopoietic processes initiated by rare LSCs that have maintained or reacquired the capacity for indefinite proliferation through accumulated mutations and/or epigenetic changes.
  • Yet, despite their critical importance, much remains to be learned about the developmental origin of LSCs and the mechanisms responsible for their emergence in the course of the disease.
  • [MeSH-major] Hematopoietic Stem Cells. Leukemia, Myeloid, Acute / pathology. Neoplastic Stem Cells

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16246162.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


85. Sung Kim M, Ki Min C, Lee S, Gyun Chung N, Jin Yoo N, Hyung Lee S: Somatic mutation of TRAF3 gene is rare in common human cancers and acute leukemias. Acta Oncol; 2008;47(8):1615-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutation of TRAF3 gene is rare in common human cancers and acute leukemias.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Mutation / genetics. Neoplasms / genetics. TNF Receptor-Associated Factor 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607851.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / TNF Receptor-Associated Factor 3; 0 / TRAF3 protein, human
  •  go-up   go-down


86. Casillas J, Sakamoto KM: Topics in pediatric leukemia--acute lymphoblastic leukemia and late effects in long-term survivors. MedGenMed; 2005;7(1):22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topics in pediatric leukemia--acute lymphoblastic leukemia and late effects in long-term survivors.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Radiotherapy / adverse effects. Surgical Procedures, Operative / adverse effects. Survivors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1993;21(5):333-9 [8492747.001]
  • [Cites] Acta Paediatr. 1993 May;82(5):459-62 [8518522.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):182-8 [8004574.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1926-34 [11283124.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2775-8 [11397886.001]
  • [Cites] Oncologist. 2001;6(3):278-85 [11423675.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 12):2-7 [11552224.001]
  • [Cites] Curr Oncol Rep. 2002 Mar;4(2):131-41 [11822985.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30 [11878576.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2959-64 [12089225.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 [12107213.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Blood Cells Mol Dis. 2003 Jul-Aug;31(1):84-92 [12850490.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1215-21 [15051768.001]
  • [Cites] Pediatr Radiol. 2004 May;34(5):373-8; quiz 443-4 [14963622.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):145-53 [15247354.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):601-3 [15295054.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] Clin Orthop Relat Res. 1977 Jun;(125):139-44 [880755.001]
  • [Cites] Med Pediatr Oncol. 1979;7(2):141-51 [291772.001]
  • [Cites] Am J Med. 1981 Jul;71(1):47-52 [6941699.001]
  • [Cites] Skeletal Radiol. 1984;11(1):13-6 [6424236.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1984 Summer;6(2):115-21 [6589968.001]
  • [Cites] Med Pediatr Oncol. 1985;13(1):14-21 [3871501.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1287-91 [3753892.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1981-7 [2121911.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1913-7 [1913542.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Pediatr Neurol. 1991 Jul-Aug;7(4):237-42 [1930413.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):13-6 [1727109.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1095-102 [1318952.001]
  • [Cites] Neuropsychol Rev. 1991 Jun;2(2):147-77 [1844707.001]
  • [Cites] Arch Dis Child. 1994 Jun;70(6):476-83 [8048815.001]
  • [Cites] JAMA. 1994 Nov 9;272(18):1427-32 [7933424.001]
  • [Cites] Baillieres Clin Haematol. 1994 Jun;7(2):365-76 [7803907.001]
  • [Cites] J Bone Miner Res. 1996 Nov;11(11):1774-83 [8915786.001]
  • [Cites] J Dev Behav Pediatr. 1996 Dec;17(6):392-8 [8960568.001]
  • [Cites] Int J Obes Relat Metab Disord. 1996 Dec;20(12):1130-2 [8968860.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):382-95 [9467546.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):545-50 [9469339.001]
  • [Cites] Pediatr Res. 1998 May;43(5):607-13 [9585006.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):234-40 [9628435.001]
  • [Cites] Pediatr Rehabil. 1997 Apr-Jun;1(2):63-76 [9689241.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):255-62 [10646874.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):217-22 [10882177.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Horm Res. 2000;53(4):193-9 [11044803.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Nov;24(11):1537-41 [11126353.001]
  • [Cites] J Pediatr Psychol. 2001 Jan-Feb;26(1):1-9 [11145727.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):770-2 [9797685.001]
  • [Cites] N Engl J Med. 1999 Feb 25;340(8):653-4; author reply 655 [10049085.001]
  • [Cites] Pediatr Res. 1999 Apr;45(4 Pt 1):544-51 [10203147.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1859-65 [10223582.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Feb;50(2):163-9 [10396357.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3207-15 [10506620.001]
  • [Cites] Psychooncology. 2004 Oct;13(10):689-99 [15386645.001]
  • (PMID = 16369327.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  • [Other-IDs] NLM/ PMC1681412
  •  go-up   go-down


87. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G, Rocha V, Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT): Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood; 2010 Apr 29;115(17):3437-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group.
  • T cell-depleted haploidentical hematopoietic stem cell transplantation (haploHSCT) is an option to treat children with very high-risk acute lymphoblastic leukemia (ALL) lacking an HLA-identical donor.
  • The 5-year leukemia-free survival (LFS) was 30%, 34%, 22%, and 0%, respectively.
  • In a multivariate analysis, haploHSCT performed in larger centers (performing > or = 231 allotransplantations in the studied period) was associated with improved LFS rate and decreased RI (adjusted P = .01 and P = .04, respectively), adjusting for different patient-, disease-, and transplant-related factors such as number of previous autotransplantations, cytomegalovirus serology status, type of T-cell depletion, and use of total body irradiation and antithymocyte globulin.
  • In conclusion, higher CD34(+) cell dose and better patient selection may improve outcomes of children with ALL who undergo a haploHSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hospitals, Pediatric. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Europe. Female. Humans. Infant. Male. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous


88. Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S, Somlo G: Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):273-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation.
  • PURPOSE: Total-body irradiation (TBI) has an important role in patients undergoing hematopoietic cell transplantation (HCT), but is associated with significant toxicities.
  • In a separate allogeneic HCT trial, 8 patients (5 with acute myelogenous leukemia, 1 with acute lymphoblastic leukemia, 1 with non-Hodgkin's lymphoma, and 1 with multiple myeloma) were treated with TMI plus total lymphoid irradiation plus splenic radiotherapy to 12 Gy (1.5 Gy twice daily) combined with fludarabine/melphalan.
  • Primarily Grades 1-2 acute toxicities were observed.
  • The reduced acute toxicities observed compare favorably with those seen with standard TBI.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1986 Feb;104(2):168-75 [3511812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1065-9 [3298176.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1562-8 [3049951.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1660-5 [2015394.001]
  • [Cites] Blood. 1994 May 1;83(9):2723-30 [8167351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):119-28 [7995742.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1455-6 [9694737.001]
  • [Cites] Semin Radiat Oncol. 1999 Jan;9(1):108-17 [10196402.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):876-84 [16199317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):227-34 [16169680.001]
  • [Cites] Bone Marrow Transplant. 2006 Mar;37(5):463-7 [16435013.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Mar;12(3):306-15 [16503500.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S74-82 [16979445.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3669-71 [11392326.001]
  • [Cites] Blood. 2002 Feb 1;99(3):731-5 [11806971.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(10):807-16 [12058230.001]
  • [Cites] Bone Marrow Transplant. 2003 Sep;32(6):543-8 [12953124.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2684-91 [12730103.001]
  • [Cites] Cancer. 1975 Sep;36(3):842-54 [1182674.001]
  • [Cites] Radiother Oncol. 1985 Dec;4(4):341-51 [3909241.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1259-67 [17336225.001]
  • (PMID = 18786784.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / PHS HHS / / 43904
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS83694; NLM/ PMC3896447
  •  go-up   go-down


89. Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B: Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol; 2010 Apr;89(4):365-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-six percent of patients progressed into acute myeloid leukaemia.
  • However, erythroid and cytogenetic responders had a significantly decreased risk of progression to acute myeloid leukaemia (p = 0.001 and p = 0.009, respectively) compared to non-responders.
  • Three and 5 years after study entry, the cumulative incidence of acute myeloid leukaemia for patients with a cytogenetic response was 10% and 21%, respectively, and for patients without cytogenetic response, it was 46% and 60%.
  • Patients with del(5q) myelodysplastic syndromes without erythroid or cytogenetic remission after treatment with lenalidomide have a high risk for clonal evolution and acute myeloid leukaemia progression.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 5. Erythroid Cells / drug effects. Leukemia, Myeloid, Acute / pathology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / pathology. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Karyotyping. Male. Middle Aged. Remission Induction. Risk Factors. Treatment Failure


90. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, SPAT Group: Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect; 2010 Dec;138(12):1804-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies.
  • Large-scale population-based studies have reported a significant increase in invasive pneumococcal disease (IPD) in those with underlying haematological or solid-organ malignancy, but limited condition-specific data are available on rates of IPD in the adult population.
  • More modestly increased rates of IPD were found in those with chronic lymphocytic leukaemia, acute myeloid leukaemia, acute lymphoblastic leukaemia, and Hodgkin's and non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429967.001).
  • [ISSN] 1469-4409
  • [Journal-full-title] Epidemiology and infection
  • [ISO-abbreviation] Epidemiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Nevruz O, Yokusoglu M, Uzun M, Demirkol S, Avcu F, Baysan O, Koz C, Cetin T, Sag C, Ural AU, Isik E: Cardiac autonomic functions are altered in patients with acute leukemia, assessed by heart rate variability. Tohoku J Exp Med; 2007 Feb;211(2):121-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac autonomic functions are altered in patients with acute leukemia, assessed by heart rate variability.
  • Acute leukemia is one of the leading malignancies worldwide.
  • Although neuropathy was reported as one of the complications of leukemia, there is a little data about the autonomic involvement.
  • This study was designed to investigate the cardiac autonomic disturbances in acute leukemias by using time-domain indices of heart rate variability (HRV).
  • Newly diagnosed 36 patients with acute leukemia (14 acute lymphoblastic leukemia and 22 acute myeloblastic leukemia) and gender- and age-matched 32 healthy subjects as controls were enrolled in this study.
  • The diagnosis of leukemia was established by whole blood count, peripheral smears and bone marrow aspirations.
  • The age, gender and serum ferritin levels were similar, while hemoglobin levels were lower in the leukemia group.
  • The comparison of the leukemia group and control group revealed that HRV decreased in patients with acute leukemia, which reflects sympathetic dominance in acute leukemia.
  • This is the first study that shows altered cardiac autonomic functions in patients with acute leukemias who are not on any therapeutical intervention.
  • The altered cardiac autonomic functions may be a sign of paraneoplastic neuropathy in patients with acute leukemia.
  • [MeSH-major] Arrhythmias, Cardiac / diagnosis. Arrhythmias, Cardiac / etiology. Leukemia / complications

  • MedlinePlus Health Information. consumer health - Arrhythmia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287595.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hemoglobins; 9007-73-2 / Ferritins
  •  go-up   go-down


92. Travaglino E, Comincini S, Benatti C, Azzalin A, Nano R, Rosti V, Ferretti L, Invernizzi R: Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes. Br J Haematol; 2005 Mar;128(6):877-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes.
  • We investigated the expression patterns and distribution of Doppel (Dpl), the product of the prion-like gene PRND, in the leukaemic cell lines HL-60 and K562 and in bone marrow cells from 44 patients with acute myeloid leukaemia (AML) and 63 patients with myelodysplastic syndrome (MDS).
  • Whereas normal samples were negative or showed very weak expression that was restricted to CD34(+) cells, Dpl was detected in both cell lines and in most AML and MDS cases by immunocytochemistry and Western blotting.
  • PRND expression was higher in advanced compared with early MDS (P = 0.01), but Dpl levels did not predict disease progression.
  • The molecular mechanism of the observed overexpression is unknown; however, the differential Dpl distribution in AML and MDS versus healthy subjects makes it a possible leukaemia-associated antigen that could be useful for diagnostic and therapeutic purposes.
  • [MeSH-major] Leukemia, Myeloid / metabolism. Myelodysplastic Syndromes / metabolism. Prions / metabolism
  • [MeSH-minor] Acute Disease. Aged. Antigens, CD34 / metabolism. Blotting, Western. Female. GPI-Linked Proteins. HL-60 Cells. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction / methods. RNA, Messenger / metabolism


93. Ryan DP, Duncan JL, Lee C, Kuchel PW, Matthews JM: Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12. Proteins; 2008 Mar;70(4):1461-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nuclear proteins TAL1 (T-cell acute leukaemia protein 1) and LMO2 (LIM-only protein 2) have critical roles in haematopoietic development, but are also often aberrantly activated in T-cell acute lymphoblastic leukaemia.
  • TAL1 and LMO2 operate within multifactorial protein-DNA complexes that regulate gene expression in the developing blood cell.
  • Here we used biophysical methods to characterize the assembly of a five-component complex containing TAL1, LMO2, Ldb1, E12, and DNA.
  • Our data provide biophysical evidence for a mechanism, by which LMO2 and TAL1 both regulate transcription in normal blood cell development, and synergistically disrupt E2A function in T-cells to promote the onset of leukaemia.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Basic Helix-Loop-Helix Transcription Factors / metabolism. Basic Helix-Loop-Helix Transcription Factors / physiology. Blood Cells. LIM Domain Proteins. Leukemia-Lymphoma, Adult T-Cell / etiology. Metalloproteins / metabolism. Metalloproteins / physiology. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins / physiology. T-Lymphocytes. TCF Transcription Factors / metabolism. TCF Transcription Factors / physiology. Transcription Factor 7-Like 1 Protein. Transcription Factors. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc.
  • (PMID = 17910069.001).
  • [ISSN] 1097-0134
  • [Journal-full-title] Proteins
  • [ISO-abbreviation] Proteins
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / LDB1 protein, human; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Multiprotein Complexes; 0 / Proto-Oncogene Proteins; 0 / TCF Transcription Factors; 0 / TCF7L1 protein, human; 0 / Transcription Factor 7-Like 1 Protein; 0 / Transcription Factors; 135471-20-4 / TAL1 protein, human; 9007-49-2 / DNA
  •  go-up   go-down


94. Jameel A, Jamil SN: Safety of cytotoxic chemotherapy during pregnancy. J Pak Med Assoc; 2007 Sep;57(9):449-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients (33%) had breast cancer, four (22%) had chronic myeloid leukaemia, two (11%) had Hodgkin's disease, two (11%) had acute myeloid leukaemia and one each had recurrent ovarian carcinoma (5.7%), soft-tissue sarcoma (5.7%), acute lymphoblastic leukaemia (5.7%) and non-Hodgkin's lymphoma (5.7%).
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasms / drug therapy. Pregnancy. Pregnancy Trimester, Second. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072640.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytotoxins
  •  go-up   go-down


95. Adjouadi M, Ayala M, Cabrerizo M, Zong N, Lizarraga G, Rossman M: Classification of leukemia blood samples using neural networks. Ann Biomed Eng; 2010 Apr;38(4):1473-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of leukemia blood samples using neural networks.
  • Pattern recognition applied to blood samples for diagnosing leukemia remains an extremely difficult task which frequently leads to misclassification errors due in large part to the inherent problem of data overlap.
  • A novel artificial neural network (ANN) algorithm is proposed for optimizing the classification of multidimensional data, focusing on acute leukemia samples.
  • The programming tool established around the ANN architecture focuses on the classification of normal vs. abnormal blood samples, namely acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML).
  • With this type of accuracy, this programming tool provides information to medical doctors in the form of diagnostic references for the specific disease states that are considered for this study.
  • The results obtained prove that a neural network classifier can perform remarkably well for this type of flow-cytometry data.
  • [MeSH-major] Algorithms. Blood Cell Count / methods. Diagnosis, Computer-Assisted / methods. Flow Cytometry / methods. Leukemia / blood. Leukemia / pathology. Neural Networks (Computer). Pattern Recognition, Automated / methods

  • MedlinePlus Health Information. consumer health - Blood Count Tests.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013155.001).
  • [ISSN] 1573-9686
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


96. Vannucchi AM: Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med; 2010 Jun;5(3):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While life expectancy may not be significantly shortened, arterial and venous thrombosis constitute the major causes of morbidity and mortality, together with disease evolution to myelofibrosis or transformation to acute leukemia.


97. Hayashi H, Fujimaki C, Inoue K, Suzuki T, Itoh K: Genetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population. Biol Pharm Bull; 2007 Apr;30(4):839-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequency of C and T allele was 0.944 and 0.056, respectively.
  • Although the frequency of variant T allele in a Japanese population is not so high as compared to Caucasians, determination of C452T polymorphism of GGH may be useful for monitoring of efficacy and side-effects of MTX for treatment of diseases such as rheumatoid arthritis or childhood acute leukemia.

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858515 for PMID:17409534 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409534.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.4.19.9 / gamma-Glutamyl Hydrolase
  •  go-up   go-down


98. Cataldi A, di Giacomo V, Rapino M, Genovesi D, Rana RA: Cyclic nucleotide Response Element Binding protein (CREB) activation promotes survival signal in human K562 erythroleukemia cells exposed to ionising radiation/etoposide combined treatment. J Radiat Res; 2006 Jun;47(2):113-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since a key role was assigned to Cyclic nucleotide Response Element Binding protein (CREB) multigenic family (which is composed of several nuclear transcription factors involved in c-AMP signalling in cell differentiation, proliferation, apoptosis, survival and adaptive response and in hematopoiesis and acute leukemias), attention was paid to the activation of Erk cascade and of the downstream kinases and transcription factors such as p90RSK and CREB.
  • K562 erythroleukemia cell survival to 1.5 Gy ionising radiation with or without etoposide treatment seemed to involve Erk phosphorylation which, regulating p90 RSK, should activate CREB.
  • [MeSH-major] CREB-Binding Protein / metabolism. Cell Survival / drug effects. Cell Survival / radiation effects. Etoposide / administration & dosage. Radiation, Ionizing

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819137.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CREBBP protein, human; 6PLQ3CP4P3 / Etoposide; EC 2.3.1.48 / CREB-Binding Protein
  •  go-up   go-down


99. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Tomonaga M: Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood; 2005 Oct 15;106(8):2633-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the first step, we analyzed agreement of morphologic diagnosis between Japanese and German hematologists.
  • Japanese patients had a significantly lower cumulative risk of acute leukemia evolution than did German patients.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Asian Continental Ancestry Group / ethnology. Child. Disease Susceptibility. Female. Germany / ethnology. Humans. Leukemia, Lymphoid / pathology. Male. Middle Aged. Prognosis. Survival Rate


100. van de Loosdrecht AA, van den Ancker W, Houtenbos I, Ossenkoppele GJ, Westers TM: Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications. Handb Exp Pharmacol; 2009;(188):319-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
  • Immunotherapy for leukaemia patients, aiming at the generation of anti-leukaemic T cell responses, could provide a new therapeutic approach to eliminate minimal residual disease (MRD) cells in acute myeloid leukaemia (AML).
  • Leukaemic blasts harbour several ways to escape the immune system including deficient MHC class II expression, low levels of co-stimulatory molecules and suppressive cytokines.
  • Alternatively, monocyte derived DC obtained at time of complete remission loaded with leukaemia-specific antigens can be used as vaccine.
  • Several sources of leukaemia-associated antigen and different methods of loading antigen onto DC have been used in an attempt to optimize antitumour responses including apoptotic cells, necrotic cell lysates and tumour-associated pep-tides.
  • Currently, the AML-derived cell line MUTZ-3, an immortalized equivalent of CD34(+) DC precursor cells, is under investigation for vaccination purposes.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Cancer Vaccines. Dendritic Cells / transplantation. Immunotherapy, Adoptive. Leukemia, Myeloid / therapy
  • [MeSH-minor] Animals. Antigen Presentation. Cell Line, Tumor. Cytokines / metabolism. Histocompatibility Antigens / metabolism. Humans. Immunological Synapses. Lymphocyte Activation. Lymphocytes, Tumor-Infiltrating / immunology. Signal Transduction. T-Lymphocytes / immunology. Treatment Outcome. Tumor Escape

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031033.001).
  • [ISSN] 0171-2004
  • [Journal-full-title] Handbook of experimental pharmacology
  • [ISO-abbreviation] Handb Exp Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Cytokines; 0 / Histocompatibility Antigens
  • [Number-of-references] 186
  •  go-up   go-down






Advertisement